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ABSTRACT 
 
Daniel W Summers 
Cytoprotective Strategies that Selectively Recognize and Suppress Protein Aggregation in the Cell  
(Under the direction of Douglas Cyr PhD) 
 
Protein misfolding and aggregation are constant threats to cellular homeostasis. The cell must 
cope with a diverse range of non-native protein conformers and efficiently triage misfolded proteins 
between pathways for refolding or degradation. In addition, cellular pathways sequester non-native 
proteins via the microtubule cytoskeleton to distinct subcellular compartments when degradation 
pathways are saturated. Deficiencies in protein homeostasis occur in a wide variety of human 
maladies. For example, several disorders including Alzheimer’s disease and Huntington’s disease are 
associated with the accumulation of beta-sheet rich, amyloid-like inclusions. Though molecular 
chaperones are known regulators of amyloid assembly and neurotoxicity, how molecular chaperones 
selectively bind beta-sheet rich protein conformers and regulate amyloid fibril assembly is largely 
unknown. Herein, I describe a novel function for the Type I Hsp40 molecular chaperone Ydj1 in 
regulating aggregation and toxicity of a glutamine/asparagine-rich prion fragment from the yeast 
protein Rnq1. In the absence of Ydj1, overexpression of this prion fragment was toxic to yeast and 
resulted in the accumulation of amyloid-like aggregates. Ydj1 binding and suppression of toxicity 
required its zinc finger-like domain and farnesyl moiety. As a result, Ydj1 utilizes unique chaperone 
modules to suppress aggregation of an amyloid-like prion and protect cells from the toxic buildup of 
protein aggregates. Ydj1 also participates in the degradation of misfolded proteins via the ubiquitin-
proteasome system. I found that Ydj1 is required to hold polyubiquitinated forms of a misfolded, 
cytosolic protein in a soluble state. Investigating the degradation of this misfolded protein further, I 
found that interfering with specific steps in the degradation pathway partitioned this misfolded protein 
to distinct outcomes including aggregation. Surprisingly, altering the microtubule cytoskeleton drove 
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this misfolded protein to form insoluble aggregates in the cytosol that could not be trafficked to the 
proteasome. Disrupting microtubule dynamics selectively stabilized some misfolded proteins, while 
other misfolded proteins are degraded in a microtubule-independent pathway. These observations 
uncover a novel connection between chaperone-mediated protein quality control and the microtubule 
cytoskeleton. Furthermore, misfolded proteins are managed in the cytosol by sophisticated quality 
control networks that utilize adaptable molecular chaperones such as Ydj1 to suppress aberrant 
protein aggregation.  
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1.1 Abstract 
Hsp40 co-chaperones assist in cellular protein folding and degradation through the binding and 
delivery of non-native proteins to Hsp70. The mechanism for substrate transfer from Hsp40s to 
Hsp70 is unknown.  Two recent studies provide new details that shed light on novel mechanisms for 
substrate recognition by Hsp40s and a common mechanism for polypeptide transfer to Hsp70. 
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1.2 Hsp70s and protein folding  
Heat shock protein 70 family members generally referred to as Hsp70 interact with different 
combinations of Hsp40s and other folding and degradatory co-chaperones to facilitate multiple 
processes required for protein homeostasis (1,2). Defects in protein homeostasis can trigger aberrant 
protein aggregation, a hallmark of a broad class of diseases known collectively as “Conformational 
Disorders”. Hsp70 molecular chaperones protect cells against the accumulation of proteotoxic species 
by maintaining a delicate balance between protein synthesis, folding, and degradation (3). Yet the 
mechanism(s) by which functionally distinct Hsp40s (also known as J-proteins) bind and deliver a 
diverse array of proteins to the polypeptide-binding site of Hsp70 remains a major unanswered 
question.  
Polypeptide binding and release by Hsp70 is coordinated via an array of co-chaperones that 
tightly regulate the Hsp70 ATP hydrolytic cycle (Fig. 1.1) (4-6). This process is initiated when a non-
native polypeptide is bound by an Hsp40 co-chaperone  (1). This large and structurally diverse family 
is defined by a highly conserved region called a J-domain that interacts with the Hsp70 nucleotide-
binding domain (NBD) and stimulates intrinsic Hsp70 ATPase activity (1,7,8). Hydrolysis of ATP to 
ADP in the Hsp70 NBD induces a conformational change in the Hsp70 substrate-binding domain 
(SBD) thus increasing Hsp70’s affinity for the substrate (9,10). In most cases, polypeptides are 
released from Hsp70 when ADP is exchanged for ATP; this reaction is facilitated by structurally 
diverse nucleotide exchange factors (NEFs) (11,12). Once released, the polypeptide can fold to the 
native conformation, or remain misfolded and reenter the cycle for subsequent rounds of refolding. 
However, in some instances Hsp70-bound clients are recognized by the E3 ubiquitin ligase CHIP 
(carboxyl terminus of Hsc70-interacting protein) and targeted for degradation by the ubiquitin-
proteasome system (13). Interestingly, Hsp70 and Hsp40 proteins have recently been identified as 
partners with additional E3 ubiquitin ligases (14). Thus, the fate of non-native polypeptides is 
determined via association of Hsp70 with co-factors that facilitate protein folding or degradation via 
the ubiquitin-proteasome system.   
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Figure 1.1. Hsp70 polypeptide binding and release is regulated through cycles of ATP 
hydrolysis and exchange. Protein misfolding is managed in part through action of Hsp70 molecular 
chaperones in coordination with various cellular cofactors. Initially, a non-native polypeptide is 
bound by an Hsp40 co-chaperone (light blue). 2) The Hsp40 J-domain then binds Hsp70 (teal) in an 
ATP-bound state. 3) J-domain-stimulated ATP hydrolysis in the nucleotide-binding domain induces a 
conformational shift in the Hsp70 substrate-binding domain, increasing affinity for the non-native 
polypeptide which is released from the Hsp40. Additional cofactors such as the E3 ubiquitin ligase 
CHIP (orange) with a ubiquitin-conjugating E2 (blue) can bind Hsp70 and the non-native 
polypeptide, targeting the substrate for degradation by the ubiquitin-proteasome system. 4) 
Nucleotide exchange factors (NEFs) such as the Hsp110s (green) replace the ADP with ATP, 
releasing the polypeptide from Hsp70. 5) If the polypeptide remains in a non-native conformation, the 
cycle can be repeated until folding is complete. 
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1.3 Hsp40s: diverse Hsp70 binding partners  
Through direct binding to non-native substrates, Hsp40s serve as conduits that funnel non-
native clients to Hsp70. Despite sharing a conserved J-domain, the Hsp40 family is extensive and 
members possess unique domains that bind diverse clients and target Hsp70 to distinct cellular 
machineries. Hsp40s are categorized based on homology to the founding member in Escherichia coli, 
DnaJ (7,8). Type I Hsp40s possess a J-domain, a glycine- and phenylalanine-rich (G/F-rich) region 
and cysteine-rich, zinc finger-like region (ZFLR). Type II Hsp40s contain the J-domain and G/F-rich 
region whereas Type III Hsp40s retain only the J-domain. Action of the Hsp40 J-domain alone is 
sufficient to enable Hsp70 perform its essential cellular functions (15). However, the specialized 
Hsp40 polypeptide binding domain discussed above impart significant influence over Hsp40 
quaternary structure and play critical roles in directing Hsp70 to carry out a variety of specialized 
functions (16),17. 
 Importantly, evolutionary diversification of the Hsp40 family has expanded the repertoire of 
the Hsp40 co-chaperone class (Fig 1.2). Recent studies suggest this structural diversification has 
generated an array of co-chaperones with unique polypeptide-binding domains that all interact with 
Hsp70 via the J-domain. This specialization is exemplified by new studies on the function of 3 
different ER-localized Hsp40s (17-19). For example, the Hsp40s P58 and ERdj3 specifically bind 
misfolded substrates in the ER lumen (18,19). However, P58 is unique because this Hsp40 contains 
nine tetratricopeptide repeats that appear to participate in recognition and binding of misfolded 
proteins. Thus, P58 and ERdj3 may discriminate between distinct nonnative substrates within the ER. 
By contrast, the Type III Hsp40 ERdj5 is associated with a supramolecular complex that targets 
misfolded ER lumenal proteins for degradation via the ER associated degradation pathways (ERAD). 
ERdj5 contains three cysteine-rich thioredoxin domains could be involved in substrate recognition 
and facilitate retrotranslocation by cleaving disulfide bonds in non-native proteins within the ER 
lumen. Thus, highly specialized ER-localized Hsp40s have evolved different mechanisms for 
substrate binding to meet the protein quality control requirements of this cellular sub-compartment.  
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Figure 1.2. Domain structures of several human Hsp40s. Type I Hsp40s such as Hdj-2 (also called 
DnaJA1) possess a J-domain, G/F-rich region (green) and a ZFLR (blue). Hdj-2 is distinct from many 
Hsp40s as it is farnesylated at a C-terminal CAAX motif. Type II Hsp40s, such as Hdj-1 (also called 
DnaJB1), lack the ZFLR. HSJ1a and HSJ1b (also called DnaJB2) are neuron-specific Type II Hsp40 
isoforms. Both isoforms possess two ubiquitin interaction motifs (UIMs:brown); however Hsj1b also 
contains a CAAX motif that is geranylgeranylated. ER-localized Hsp40s have also evolved 
specialized domains. For example, ERdj3 (also called DnaJB11) contains a cysteine-rich motif (gray) 
in the C-terminus (21). P58 (also called DnaJC3) contains nine tetratricopeptide repeats (TPR:red) 
that might bind non-native polypeptides while ERdj5 contains three thioredoxin (TRX;yellow) 
domains which are responsible for disulfide reductase activity. The length of each Hsp40 represents 
its relative size. The intracellular location of each Hsp40 is noted.  
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A unique feature of cytosolic Hsp40s is the modification of Type I and Type II family 
members by prenylation (1,7,8). For example, the yeast Type I Hsp40 Ydj1p and its human homolog 
Hdj-2 are farnesylated at a C-terminal CAAX motif (20). Whereas this lipid modification helps 
localize a pool of Hsp40 to the cytosolic surface of the ER membrane, one recent study suggests that 
farnesylation is required for Type I Hsp40s to bind specific substrates (21). In addition, the neuron-
specific Type II Hsp40 HSJ1b is geranylgeranylated and localized to the ER surface. Similar to Type 
I Hsp40s, binding between HSJ1b and its client protein rhodopsin relies on this lipid modification 
(22). Thus, lipid modification not only affects localization, but might also stabilize Hsp40–
polypeptide complexes.   
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1.4 Polypeptide transfer and release from Hsp70 
Once Hsp40s bind non-native polypeptides, bound clients must be transferred to Hsp70 for 
subsequent processing. To begin to address how this occurs, given the extensive structural diversity 
within the Hsp40s, Petrova et al (18) and Jin et al (19) recently examined how two different ER-
localized Hsp40s release substrates upon interaction with the Hsp70 BiP. In these studies, the Hsp40s 
P58 and ERdj3 specifically bound misfolded or denatured substrates. Efficient substrate release from 
either Hsp40 relied upon interaction between BiP and the J-domain, specifically when BiP was ATP-
bound. Mutational analysis of BiP revealed that substrate release was functionally coupled to BiP’s 
ATPase activity suggesting that a J-domain–BiP complex was not sufficient to dissociate the 
substrate. How does Hsp70 binding and ATP hydrolysis provoke Hsp40 to release its substrate? One 
hypothesis is that binding to Hsp70 induces an allosteric shift in the Hsp40 that reduces substrate 
affinity in the polypeptide-binding domain. However, Petrova et al (16) found that the location of the 
J-domain within the Hsp40 was inconsequential to BiP-induced substrate release. Furthermore, the 
extensive variation present in the Hsp40 family argues against a unified allosteric mechanism. 
However, J-domain–Hsp70 binding might bring the substrate in close proximity to the Hsp70 SBD. 
Following ATP hydrolysis, the increase in substrate affinity by Hsp70 could then out-compete the 
Hsp40 for binding.   
This new model explains how divergent Hsp40s can uniformly release substrates for transfer 
to Hsp70 through interactions between the conserved J-domain and the Hsp70 NBD. However, some 
Hsp40s interact with regions within the Hsp70 SBD (23), suggesting that specific Hsp40s have 
evolved individualized mechanisms for cooperating with Hsp70. Ydj1p, in particular, requires its 
ZFLR for substrate transfer and chaperone-dependent refolding (24). The Ydj1p ZFLR (located 
immediately adjacent to the J-domain) might help orient substrates in a more amenable position for 
transfer to the Hsp70 SBD (16). Therefore, distinct Hsp40 modules might confer not only unique 
binding preferences, but also specialized interactions with Hsp70 that impart significant regulatory 
oversight in this relationship.  
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Polypeptide release from Hsp70 is mediated by exchange of ADP for ATP. The NEFs that 
regulate this step are also highly diverse; they do not share a common domain responsible for this 
activity. Several recent structures suggest that individual NEFs might function by twisting the lobes 
of the Hsp70 ATPase domain in a manner that decreases affinity for ADP (12). Interestingly, the NEF 
Sse1p and its human homologs are non-canonical Hsp70s that possesses polypeptide-binding activity 
and might interact with Hsp70-bound clients (25). Thus, sequential interactions between non-native 
polypeptides with Hsp40, Hsp70 and other Hsp70 co-chaperones appear to play critical roles in 
cellular folding and degradation pathways.  
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1.5 Concluding Remarks  
 Hsp40 co-chaperones have emerged as complex and essential players in regulating protein 
homeostasis. This diverse family utilizes a variety of mechanisms to bind and funnel clients to Hsp70. 
Yet, recent studies suggest a uniform mechanism for substrate release and transfer from Hsp40 to 
Hsp70 (18,19). Future studies are needed to dissect how specialized Hsp40s selectively recognize 
different protein conformers and specify Hsp70s cellular functions.  In addition, we need to 
understand how interactions between Hsp70-bound protein clients and folding and degradatory co-
chaperones mediate protein triage events (13,25).  Further knowledge of this process will lend critical 
insight into the underlying causes and potential treatments for the expansive list of Protein 
Conformational Disorders. 
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2.1 Abstract 
Molecular chaperones regulate essential steps in the propagation of yeast prions. Yeast prions possess 
domains enriched in glutamines and asparagines that act as templates to drive the assembly of native 
proteins into beta-sheet-rich, amyloid-like fibrils. Several recent studies highlight a significant and 
complex function for Hsp40 co-chaperones in propagation of prion elements in yeast. Hsp40 co-
chaperones bind non-native polypeptides and transfer these clients to Hsp70s for refolding or 
degradation. How Hsp40 co-chaperones bind amyloid-like prion conformers that are enriched in 
hydrophilic residues such as glutamines and asparagines is a significant question in the field. 
Interestingly, selective recognition of amyloid-like conformers by distinct Hsp40s appears to confer 
opposing actions on prion assembly. For example, the Type I Hsp40 Ydj1 and Type II Hsp40 Sis1 
bind different regions within the prion protein Rnq1 and function respectively to inhibit or promote 
[RNQ
+
] prion assembly. Thus, substrate selectivity enables distinct Hsp40s to act at unique steps in 
prion propagation. 
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2.2 Molecular chaperones and yeast prions 
Proteins adopt a diverse and dynamic array of structural conformations. Prions are unique in 
that these proteins induce conversion of the soluble, native structure into the prion conformer with a 
high propensity to self-assemble into beta-sheet-rich, amyloid-like fibrils.(1) Extensive investigation 
of prion biogenesis in the budding yeast Saccharomyces cerevisiae has uncovered some of the basic 
mechanisms underlying prion assembly into amyloid-like fibrils and inheritance of the prion state. 
One intriguing development in this story was the intimate role for heat shock protein (HSP) molecular 
chaperones in these pathways.(2,3) Indeed, numerous yeast prions are dependent upon molecular 
chaperones for efficient maintenance and propagation of prion structures.(4,5) On the other hand, 
overexpression of some molecular chaperones “cure” yeast of the heritable prion suggesting 
molecular chaperones antagonize prion assembly.(4,6,7) How such opposing activities efficiently 
coordinate prion assembly into amyloid-like fibrils and propagation of the prion state inside the cell is 
an outstanding question in the field. Study of this process is significant because amyloid-like fibrils 
accumulate in numerous conformational disorders.(8,9) However, the connection between amyloid 
assembly and neuronal cell death is still controversial as several recent studies implicate the assembly 
of amyloid-like fibrils as benign or even protective.(10-12) In addition, prions found in S. cerevisiae 
possess domains enriched in glutamines (Gln) and asparagines (Asn)(13), resembling proteins with 
expanded polyglutamine repeats (such as human huntingtin and several ataxins) that are very 
susceptible to aggregation.(14,15) Many molecular chaperones are functionally conserved from yeast 
to humans, and as such, studying how molecular chaperones modulate prion propagation yields 
substantial mechanistic insight on the regulation of amyloid assembly in conformational disorders. 
Several classes of molecular chaperone are implicated in prion propagation. For example, the 
AAA+ protein remodeling factor Hsp104 is required for propagation of several prions in 
yeast.(4,16,17) Hsp104 is proposed to shear prion polymers to generate “seeds” that drive conversion 
of native protein into the prion conformation.(18-21) Hsp70 molecular chaperones also regulate prion 
propagation although the particular function depends on the Hsp70 class and specific yeast prion. For 
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example, mutations in the Hsp70 Ssa1 destabilize [PSI
+
] prion propagation while overexpression of 
Hsp70s from the Ssa family can stabilize the [PSI
+
] state.(22-24) Interestingly, overexpression of 
Ssa1 has been shown to cure yeast of the prion [URE3].(6,7) In contrast, Hsp70s of the Ssb family 
appear to antagonize [PSI
+
] prion propagation.(24-26) As a result, protein flux through Hsp70 
refolding pathways is a crucial step in prion biogenesis. Hsp70 chaperone activity is tightly 
coordinated by Hsp40 co-chaperones (also known as J-proteins). Additionally, Hsp40 and Hsp70 
chaperones cooperate with Hsp104 to refold aggregated proteins.(27) Several recent studies 
underscore a complex, yet fundamental role for Hsp40 co-chaperones in prion assembly and 
propagation.(5,12,28-31) In this review we first describe the Hsp40 co-chaperone family and basic 
mechanisms underlying Hsp40:substrate recognition. Then, general roles for Hsp40s in propagation 
of the yeast prions [PSI
+
] and [URE3], and [RNQ
+
]/[PIN
+
] are discussed. Recent studies investigating 
the function of Hsp40s on assembly of the [RNQ
+
] prion are emphasized to highlight novel 
mechanisms in which Hsp40s bind Gln/Asn-rich prion proteins and modulate the accumulation of 
toxic or benign prion conformers. We propose that the distinct binding preferences of individual 
Hsp40s determine specific Hsp40 actions in prion assembly and propagation. 
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2.3 Protein Quality Control by Hsp40 Molecular Chaperones 
 Hsp40 co-chaperones are essential partners in Hsp70 function.(32) Hsp40s share a highly 
conserved region called a J-domain that stimulates the intrinsic ATPase activity of its partner 
Hsp70.(33) ATP hydrolysis causes a series of conformational changes that increase the affinity of 
client:Hsp70 interactions.(34,35) Client release from Hsp70 is induced when ADP is replaced with 
ATP by a Hsp70 nucleotide exchange factor.(36) The Hsp40 J-domain alone appears sufficient to 
maintain basic cellular processes required for physiological growth.(37) However, based upon 
homology to the J-domain from the founder Hsp40 in Escherichia coli (DnaJ), there are twenty-two 
Hsp40s in budding yeast and forty-one Hsp40s in humans.(32,38) Given the evolutionary expansion 
of the Hsp40 family, how these various Hsp40s specify Hsp70 function is an important unanswered 
question.  
Importantly, Hsp40s utilize a variety of specialized domains outside of the J-domain to bind 
misfolded polypeptides and transfer these non-native clients to Hsp70 for refolding or 
degradation.(39,40) Thus, Hsp40s select substrates for Hsp70 chaperone action and serve as the first 
line of defense in protein conformational disorders by recognizing non-native protein conformers. 
Hsp40s are classified based on the presence of several core domains found in DnaJ. Type I Hsp40s 
possess a J-domain, glycine/phenylaline(G/F)-rich region, and a zinc finger-like region (ZFLR)(Fig. 
2.1). Type II Hsp40s possess the J-domain and G/F-rich region while Type III Hsp40s retain only the 
J-domain. The core Hsp40 domains described above influence Hsp40 quaternary structure and 
substrate selectivity (Fig. 2.1B).(41,42) Specialized Hsp40s have further acquired unique domains 
and modifications that likewise influence substrate preferences as well as regulation of Hsp70 
refolding activity.(43-45) For example, the yeast Type I Hsp40 Ydj1 possesses a hydrophobic 
depression in its C-terminal domain that binds hydrophobic peptides(46) as well as a CaaX motif that 
is modified by farnesylation.(47) Interestingly, the Ydj1 ZFLR, hydrophobic polypeptide-binding 
pocket, and farnesyl modification all have been shown to participate in substrate binding.(29,46,48) 
yet specific features are either necessary or dispensable for binding to individual substrates. Thus, 
18 
 
Hsp40s can utilize various domain combinations to bind a wide range of non-native clients. The yeast 
Type II Hsp40 Sis1 also possesses a hydrophobic polypeptide-binding pocket(49) yet does not 
contain a ZFLR nor a CaaX motif. However, Sis1 does contain a G/M-rich region adjacent to the 
G/F-rich region,(50) both of which appear to influence essential cellular functions of this Hsp40.(51) 
While Ydj1 and Sis1 exhibit some overlapping physiological function,(52,53) these Hsp40s also 
display distinct substrate preferences(41) and as discussed below, exert very different activities on 
propagation of prions in yeast.  
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Figure 2.1 Domain structures of the Type I Hsp40 Ydj1 and Type II Hsp40 Sis1 (A). Both 
Hsp40s possess N-terminal J-domains and adjacent G/F-rich regions. Ydj1 also contains a zinc 
finger-like region with two zinc-binding domains (denoted as I and II). Sis1 contains a G/M-rich 
region in addition to the G/F-rich region. C-terminal domains (CTD) in these Hsp40s share limited 
homology although both possess hydrophobic polypeptide-binding pockets (PBP) and dimerization 
domains (DD). Furthermore, Ydj1 is farnesylated at a C-terminal CaaX motif. (B) Quaternary 
structures of Ydj1 and Sis1 homodimers (for details see Ref. 42). The polypeptide-binding pockets of 
each Hsp40 are noted by a small grove in the C-terminus. While the J-domains are highly conserved 
between Ydj1 and Sis1, the orientations of these domains with respect to the polypeptide-binding 
pocket are very different. 
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2.4 Hsp40 activity in propagation of [PSI
+
] and [URE3] prions  
Studies of the yeast prions [PSI
+
] and [URE3] have identified complex roles for Hsp40 co-
chaperones in prion propagation and assembly into amyloid-like fibrils. The inheritable element 
[PSI
+
] is formed by the yeast translation termination factor Sup35.(18,54) Both Ydj1 and Sis1 
physically associate with large Sup35 aggregates,(55) though propagation of the [PSI
+
] prion is 
specifically dependent upon Sis1.(5,30) On the other hand, overexpression of Ydj1 in conjunction 
with its cognate Hsp70 destabilizes “weak” [PSI+] variants.(6) Also noteworthy, overexpression of 
Apj1 (another Type I Hsp40 in yeast) cures cells of specific [PSI
+
] variants.(56) Apj1 shares strong 
homology with Ydj1 yet its cellular functions are still unclear. Recent studies on Sup35 fibril 
assembly in vitro have demonstrated a direct role for Hsp40 molecular chaperones in regulating the 
assembly of amyloid-like fibrils.(31,57) Interestingly, select Hsp40:Hsp70 pairs exert different 
actions on Sup35 assembly as well as the prion remodeling activity of Hsp104.(58) Therefore, distinct 
chaperone complexes might selectively regulate prion assembly and propagation to alternate 
outcomes. 
Hsp40s also regulate propagation of the yeast prion [URE3]. The [URE3] prion is formed by 
Ure2, a modulator of nitrogen catabolism in yeast.(59) Similar to [PSI
+
], propagation of the [URE3] 
prion requires Sis1(5) while overexpression of the Ydj1 cures yeast of [URE3].(16) Furthermore, 
Ydj1 inhibits the in vitro assembly of Ure2 into amyloid-like fibrils.(60,61) In recent studies though, 
overexpression of J-domains from other yeast Hsp40s was shown to be sufficient to cure yeast of the 
[URE3] trait.(5,62) These data indicate that modulating cycles of Hsp70 activity in the cell perturb 
[URE3] prion biogenesis and inheritance. This effect seems specific for the [URE3] prion,(5) 
suggesting this yeast prion is particularly sensitive to aberrations in prion flux through Hsp70 
refolding pathways. Altogether, Sis1 and Ydj1 drive [PSI
+
] and [URE3] propagation to completely 
different outcomes whereby Sis1 promotes the efficient propagation of prion elements yet Ydj1 
antagonizes this pathway. However, studies on [PSI
+
] and [URE3] propagation have not revealed the 
molecular mechanisms underlying these divergent chaperone actions.  
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2.5 Selective recognition of the [RNQ
+
] prion by opposing Hsp40 activities 
 Studies of the yeast prion [RNQ
+
] have recently revealed novel mechanisms by which Hsp40 
co-chaperones bind amyloid-like prion conformers and perhaps regulate prion propagation pathways 
to distinct endpoints. The yeast prion [RNQ
+
]/[PIN
+
] is formed by the yeast protein Rnq1 (rich in 
asparagines and glutamines) (Fig. 2.2A).(63,64) The [RNQ
+
] state facilitates the conversion of other 
prions in yeast(64,65) as well as seeding toxic conformers of an expanded glutamine form of human 
huntingtin.(66) Rnq1 possesses a C-terminal Gln/Asn-rich prion domain that is sufficient to assemble 
into amyloid-like fibrils in vitro(67,68) and induce prion formation when fused in place of the 
Gln/Asn-rich N-terminal domain of Sup35.(63) The N-terminal non-prion domain of Rnq1 appears to 
regulate [RNQ
+
] prion propagation though the function of this domain is still unclear.(69) Not long 
after [RNQ
+
] was first described, propagation of [RNQ
+
] prions was shown to be dependent upon 
Sis1.(70) Deletion of other Hsp40s in yeast has no effect on the [RNQ
+
] state suggesting this 
dependency is specific for Sis1.(5) In contrast to Sis1, overexpression of Ydj1 cures yeast of some 
[RNQ
+
] prion variants.(71) Thus, similar to other yeast prions discussed above, Sis1 promotes 
[RNQ
+
] propagation while Ydj1 can inhibit [RNQ
+
] assembly perhaps reflecting distinct fundamental 
functions for these two Hsp40 co-chaperones in the prion assembly pathway (Fig. 2.2B).  
What might account for the opposing functions of Sis1 and Ydj1 on [RNQ
+
] prion 
propagation? Recent studies demonstrated that Sis1 and Ydj1 bind to different regions within the 
Rnq1 protein. For example, Sis1 binds a short, hydrophobic motif in the non-prion domain(12) while 
Ydj1 binds numerous motifs in the Gln/Asn-rich prion domain of Rnq1 (Fig. 2.2A).(29) Interestingly, 
interaction between Rnq1 and either Hsp40 is dependent upon the [RNQ
+
] prion conformation.(29,70) 
Conformational conversion of native Rnq1 into the [RNQ
+
] prion state might expose the Sis1-binding 
site in the non-prion domain. This provides a mechanism by which Sis1 action in [RNQ
+
] propagation 
is regulated through conformation-specific recognition by an Hsp40 co-chaperone. Binding between  
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Figure 2.2. Domain structure of Rnq1 from S. cerevisiae (A). Rnq1 contains a N-terminal non-
prion domain (aa1-152) and a C-terminal, Gln/Asn-rich prion domain (aa153-405). Sis1 binds a short, 
hydrophobic motif in the non-prion domain while Ydj1 binds numerous motifs in prion domain. (B) 
Model for Hsp40 action in [RNQ
+
] prion assembly pathway. Native Rnq1 is converted to the [RNQ
+
] 
prion state and assembles into large, [RNQ
+
] prion aggregates that are sheared to generate heritable 
[RNQ
+
] prion seeds. Sis1 might facilitate shearing to maintain a pool of [RNQ
+
] prion seeds thereby 
propagating the [RNQ
+
] prion state. In addition Sis1 might promote the elongation of [RNQ
+
] prion 
particles. In contrast, Ydj1 might antagonize [RNQ
+
] prion assembly through binding an early 
[RNQ
+
] prion conformer thus hindering [RNQ
+
] assembly or by accelerating the disassembly of large, 
[RNQ
+
] prions such that Rnq1 is eventually converted to its native state. 
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Ydj1 and the Gln/Asn-rich prion domain of Rnq1 is quite surprising because peptide array studies 
suggest Type I Hsp40s such as Ydj1 prefer substrates enriched in hydrophobic residues.(41,72,73)  
Furthermore, select binding to the Rnq1 prion domain in the [RNQ
+
] prion state implies that Ydj1 
recognizes the Gln/Asn-rich motifs in a conformation-specific manner. Altogether, two Hsp40s in the 
cell bind [RNQ
+
] prions yet target different regions in the Rnq1 protein. The outcome of such binding 
preferences might (at a rudimentary level) account for the disparate chaperone activities on [RNQ
+
] 
prion propagation.  
What features in Ydj1 and Sis1 direct these Hsp40 chaperones to bind distinct domains 
within Rnq1? Interestingly, binding between Ydj1 and the Rnq1 prion domain is dependent upon the 
Ydj1 ZFLR and farnesylation at its C-terminal CaaX motif.(29) The Ydj1 ZFLR is adjacent to two 
anti-parallel beta-strands that might bind the beta-rich Rnq1 prion domain through a beta-strand donor 
mechanism.(74,75) How lipid modification of an Hsp40 co-chaperone contributes to substrate 
interaction is unclear, although farnesylation of Ydj1 has been implicated in binding to the kinase 
Ste11.(48) Thus, farnesylation appears required for binding to numerous chaperone substrates 
including yeast prions. In contrast, Sis1-dependent maintenance of the [RNQ
+
] prion state requires 
unique extensions in the G/F-rich region of Sis1.(76) These observations collectively suggest that 
Hsp40 co-chaperones rely on specialized modules to bind distinct domains in Rnq1 and regulate 
different aspects of [RNQ
+
] prion propagation.  
Given such discrete binding preferences, how might Sis1 and Ydj1 exert their opposing 
activities on [RNQ
+
] prion propagation? Importantly, Sis1 binds to Rnq1 in a near 1:1 stoichoimetric 
complex while binding between Ydj1 and Rnq1 (or its Gln/Asn-rich prion domain) appears 
substoichiometric.(29,76) Sis1 might coat [RNQ
+
] prion assemblies via binding the Rnq1 non-prion 
domain, direct Hsp70/Hsp104 molecular chaperones to [RNQ
+
] fibrils, and facilitate shearing to 
generate heritable [RNQ
+
] prion seeds.(28,30) In addition, Sis1 might facilitate addition of new Rnq1 
subunits into an elongating [RNQ
+
] fibril because overexpression of Sis1 increases the pool of 
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amyloid-like [RNQ
+
] assemblies while overexpression of Hsp70 and Hsp104 does not result in such 
an increase.(12)   
In contrast to Sis1, Ydj1 might cap the exposed ends of [RNQ
+
] prion assemblies and thereby 
inhibit fibril elongation by sterically hindering contacts between exposed Gln/Asn-rich motifs in the 
[RNQ
+
] prion conformer. In addition, Ydj1 might bind a [RNQ
+
] prion assembly intermediate and 
cooperate with Hsp70 to refold the Rnq1 protein into its native conformation or partition this protein 
conformer into an alternative off-pathway assembly that is subsequently remodeled by another 
chaperone complex.(77) The net result of either mechanism would be solubilization of assembled 
Rnq1 and loss of the [RNQ
+
] prion trait. Importantly, Sis1 activity must normally out-compete Ydj1 
to promote efficient [RNQ
+
] propagation. This might occur because Sis1-binding to Rnq1 is 
stoichiometric(76) and Ydj1-binding motifs in the Rnq1 prion domain are buried within most [RNQ
+
] 
assemblies. Furthermore, some but not all [RNQ
+
] prion variants are sensitive to Ydj1 
overexpression(71) suggesting that Ydj1 may differentially recognize Rnq1 prion domain surfaces 
exposed in specific [RNQ
+
] prion variants.  
These studies provide novel insight on the selectivity of Hsp40 interaction with amyloid-like 
substrates, yet several significant questions still remain. For example, if Sis1 and Ydj1 bind distinct 
domains in Rnq1 do these co-chaperones bind simultaneously to the same Rnq1 protein or do Sis1 
and Ydj1 act on discrete [RNQ
+
] intermediates/assemblies? Future studies will be required to dissect 
this question conclusively, yet the answer will likely reveal significant insight on the basic 
mechanisms of chaperone recognition of amyloid-like protein species in conformational disorders.  
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2.6 Hsp40s protect cells from toxic prion conformers 
The study of Hsp40 action in [RNQ
+
] assembly has further revealed that Sis1 and Ydj1 
protect the cell from the accumulation of cytotoxic protein conformers. Overexpression of Rnq1 is 
toxic to yeast in the presence of pre-existing [RNQ
+
] prion.(12) Importantly, overexpression of Sis1 
suppresses cytotoxicity caused by excess Rnq1, an effect that correlates with enhanced [RNQ
+
] prion 
assembly into SDS-insoluble aggregates and a decrease in the pool of SDS-soluble, Rnq1 protein 
species. Furthermore, mutating the Sis1-binding site in the Rnq1 non-prion domain decreases the 
efficiency of [RNQ
+
] prion assembly and exacerbates toxicity.(12) Thus, chaperone-mediated [RNQ
+
] 
assembly appears protective although the specific nature of the cytotoxic protein conformer is still 
unclear.  
In contrast to full length Rnq1, overexpression of the Rnq1 prion domain alone is not toxic to 
yeast.(12) However, overexpression of this prion fragment becomes toxic in the absence of Ydj1.(29) 
Unlike full-length Rnq1, whose toxicity correlated with the appearance of a low molecular weight, 
soluble protein species, the toxicity by the Rnq1 prion domain in a ydj1-null background correlated 
with an increase in the pool of large, SDS-insoluble assemblies.(29) Thus, Ydj1 might be required for 
the cell to tolerate excessive levels of large, amyloid-like species, although this point requires further 
investigation. Altogether, the above observations suggest a model in which Sis1 and Ydj1 coordinate 
the flux of Rnq1 proteins through the [RNQ
+
] prion assembly pathway in order to maintain the 
accumulation of soluble versus amyloid-like particles within a tolerable threshold for the cell. 
Interestingly, Sis1 and Ydj1 were previously shown to have opposing effects on aggregation and 
toxicity of an expanded polyglutamine model in yeast.(78) Altogether, Hsp40 co-chaperones 
selectively bind non-native protein species to either maintain protein solubility or drive 
aggregation.(79) Even though amyloid assembly can be protective it is important to consider that 
excessive amyloid burden might also result in cell death.(80) Susceptibility to various amyloid-like 
protein conformers is likely dependent upon the global expression pattern of environmental factors 
that buffer proteotoxicity.(81)  
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2.7 Concluding Remarks and Future Directions 
Hsp40 molecular chaperones have recently emerged as critical regulators of prion 
propagation in yeast. Interestingly, individual Hsp40s modulate discrete steps in the prion assembly 
pathway and in the case of Ydj1 and Sis1, execute opposing activities on propagation of several yeast 
prions. Such disparate activities might originate from the unique binding preferences exhibited the 
Hsp40 co-chaperone family, including recognition of Gln/Asn-rich regions responsible for assembly 
into beta-rich amyloid-like fibrils. Sis1 and Ydj1 possess unique structural domains that might 
account for such differential binding preferences.(41) For example, Ydj1 utilizes its ZFLR and a 
farnesyl moiety to bind the prion domain of Rnq1.(29) These features are conserved in various human 
Hsp40s and might contribute to the recognition of expanded polyglutamine conformers in various 
human diseases.(82-84) Studies of Hsp40 action in [RNQ
+
] assembly have also demonstrated that 
Sis1-mediated acceleration of [RNQ
+
] prion assembly is cytoprotective.(12) Such a role for an Hsp40 
chaperone in cytoprotection is consistent with other recent observations that facilitated protein 
aggregation protects against cell death mediated by Abeta(1-42)(85,86) and the expanded 
polyglutamine huntingtin(77,87,88) altogether suggesting that multiple protein quality control 
pathways might exist to cope with the accumulation of toxic protein conformers. Thus, dissecting 
how Hsp40s selectively recognize toxic protein species and recruit other chaperone complexes (such 
as Hsp70 and Hsp104) will yield significant insight on how aggregation pathways are regulated in 
human conformational disorders.  
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3.1 Abstract 
The formation of amyloid-like fibrils is a hallmark of several neurodegenerative diseases. How the 
assembly of amyloid-like fibrils contributes to cell death is a major unresolved question in the field. 
The budding yeast Saccharomyces cerevisiae is a powerful model organism to study basic 
mechanisms for how cellular pathways regulate amyloid assembly and proteotoxicity. For example, 
studies of the amyloidogenic yeast prion [RNQ+] have revealed novel roles by which molecular 
chaperones protect cells from the accumulation of cytotoxic protein species. In budding yeast there 
are a variety of cellular assays that can be employed to analyze the assembly of amyloid-like 
aggregates and mechanistically dissect how cellular pathways influence proteotoxicity. In this review, 
we describe several assays that are routinely used to investigate aggregation and toxicity of the 
[RNQ+] prion in yeast.   
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3.2. Introduction 
An extensive group of neurodegenerative disorders are characterized by the formation of 
amyloid-like fibrils, including Alzheimer’s disease, Huntington’s disease, and Creutzfeldt-Jakob 
disease (1). Amyloid-like fibrils are composed of β-sheet-rich conformers of a non-native protein that 
are assembled in a unique structure called a cross-β spine (2).This structure confers several unique 
properties that distinguish amyloid-like fibrils from amorphous, or disordered aggregates including 
resistance to proteases and insolubility in ionic detergents (3). While the accumulation of amyloid 
deposits is a diagnostic biomarker of amyloidosis, the connection between the assembly of amyloid-
like fibrils and neuronal cell death is currently unclear (4-6). Furthermore, specific neuronal 
subpopulations are selectively susceptible to misfolding and aggregation of particular disease proteins 
suggesting there are complex cellular pathways that influence amyloid assembly and proteotoxicity.  
Our understanding of this process is still rudimentary and many questions remain to be answered.   
There are numerous model organisms available to study amyloid-linked diseases. While 
every model organism has unique benefits and limitations, studies in the budding yeast 
Saccharomyces cerevisiae have provided substantial insight on mechanisms underlying the assembly 
of amyloid-like fibrils and proteotoxicity (7). Several proteins in S. cerevisiae known collectively as 
yeast prions can exist in a beta-rich conformation that possesses a high propensity to assemble into 
amyloid-like fibrils inside the cell (8). Molecular chaperones shear these amyloid-like assemblies to 
generate a steady pool of prion seeds that convert the native form of the protein into the beta-rich 
prion conformation and propagate the prion state (9). While studies on yeast prion biogenesis have 
centered on the yeast prions [PSI+] and [URE3], the prion [RNQ+]/[PIN+] has recently emerged as a 
powerful tool in the study of amyloid-linked toxicity in yeast. The [RNQ+] prion is formed by the 
yeast protein Rnq1 (10,11). Like other proteins that propagate as prions in budding yeast, Rnq1 
possesses a domain enriched in glutamine/asparagines residues that is sufficient to assemble into 
amyloid-like fibrils and propagate as a prion (12-14). Interestingly, the induction of other prions in 
yeast requires Rnq1 to be in the [RNQ+] state. Rnq1 has no other known function in the cell outside 
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of this role in prion induction although yeast strains isolated in the wild are predominantly in a 
[RNQ+] state (15) suggesting there may be an important, yet undiscovered function for this prion 
(16). In addition, expression of the expanded-polyglutamine form of huntingtin is selectively toxic to 
yeast when Rnq1 is the [RNQ+] prion conformation (17). Thus, the [RNQ+] prion influences 
aggregation and toxicity of other glutamine-enriched proteins in yeast although the mechanism 
underlying this relationship is unclear. 
 Importantly, overexpression of Rnq1 is toxic to yeast specifically in the presence of the 
[RNQ+] prion (18). Toxicity was correlated with the accumulation of a soluble, non-amyloid-like 
Rnq1 protein species and chaperone-dependent [RNQ+] assembly protected cells from Rnq1-induced 
toxicity.  Therefore, aberrations in [RNQ+] prion biogenesis can result in the accumulation of 
proteotoxic species and further investigation into this pathway will likely yield additional discoveries 
on how amyloid assembly pathways contribute to cell death. This review will describe a variety of 
assays to analyze Rnq1-induced toxicity and methods for characterizing amyloid-like aggregates in 
yeast. 
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3.3 Basic methods for culturing yeast 
Methods for culturing and manipulating yeast are well-established and readily available (19). 
As such, this section will focus primarily on central guidelines for growing yeast cultures to study 
amyloid assembly and toxicity. All experiments described herein were performed at 30°C although 
the specific experimental temperature may vary depending upon the optimal growth conditions for the 
yeast strain background. Plasmids expressing aggregation-prone proteins can easily be transformed 
into yeast and maintained under selection by utilizing auxotrophic markers (ex. amino acids).  
Individual colonies are used to inoculate liquid cultures that can be expanded into liter-size volumes 
as long as cultures are properly aerated and nutrient-rich. The ability to collect large quantities of cells 
is one of the distinct advantages of using budding yeast over most other model systems. The most 
important consideration when culturing yeast is to maintain the cells in log-phase growth by 
consistently diluting cells in fresh media. However, yeast cells will undergo physiological changes 
similar to aging after repetitive diluting or indefinite time in stationary phase (20). As a result, 
exogenous plasmids should be freshly transformed to improve reproducibility between experiments.  
One additional advantage to working with budding yeast is the availability of diverse 
promoters (both inducible and constitutive) that provide extensive flexibility in the time and level of 
protein expression. Inducible promoters are particularly important when studying proteotoxicity 
because the expression of a toxic protein needs to be tightly controlled during an experiment.  One of 
the more common promoters for this kind of analysis is the GAL1 promoter (21). As described below, 
this promoter is often used to examine how high level expression of a disease protein impacts cell 
viability by spotting assays or growth curves. There are several advantages to using the GAL1 
promoter for this kind of analysis.  Expression from this promoter is repressed in the presence of 
glucose permitting very robust control of protein expression.  To facilitate rapid expression from the 
GAL1 promoter, yeast cells are initially grown in media containing raffinose as the carbon source 
because raffinose does not induce or repress expression from the GAL1 promoter. Addition of 
galactose to the media rapidly induces protein expression within 30 minutes. One drawback is that 
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expression from the GAL1 promoter cannot be titrated by varying the levels of galactose. 
Furthermore, some yeast strains are unable to unable to metabolize galactose and are thus inviable 
when galactose is the sole carbon source.  
In contrast to the GAL1 promoter, the CUP1 promoter can be tightly controlled by varying 
levels of copper sulfate added to the media. Expressing a toxic protein such as Rnq1 from the CUP1 
promoter can inhibit cell growth (22); however, caution should be exercised if levels of copper sulfate 
cause growth defects independent o f protein expression. This promoter is also used to constitutively 
express a protein of choice using low levels of copper sulfate (ex. 50μM or lower). Long-term, low 
level expression of an aggregation-prone protein such as Rnq1 allows the exogenous protein to reach 
steady state equilibrium with cellular pathways that regulate assembly of amyloid-like aggregates. As 
such, Rnq1 aggregation can be studied under conditions when this protein is not toxic to yeast and 
independent of changes in cell physiology that might accompany cytotoxicity.  Constitutive, high 
level expression can also be achieved using promoters from housekeeping enzymes such as 
glyceraldehyde-3-phosphate dehydrogenase (GPD) or alcohol dehydrogenase (ADH). These 
promoters are powerful tools to analyze how overexpression of various cellular factors affects 
amyloid assembly and toxicity.  
Expression constructs can also be placed in different plasmid backbones with unique 
elements that control the plasmid copy number within the cell (19).  For example, episomal (2μ) 
vectors vary from 10-40 copies per cell and thus provide high levels of expression yet also display 
extensive variation from cell to cell. These plasmids are generally used in growth assays (ex. high 
copy suppressor screens) where cell to cell variation is not visible in measurements of population 
growth. Centromeric (CEN) plasmids are maintained at approximately 1-3 plasmids per cell and thus 
display more consistency in expression from cell to cell, yet also result in lower expression levels. To 
maintain consistent expression from cell to cell, expression constructs can also be integrated into the 
yeast genome. Ultimately, the decision to use one plasmid backbone may depend upon the specific 
protein of choice and the experimental context. 
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In the context of studying prion biogenesis, budding yeast offer one unique advantage over 
other model systems. Yeast strains can be “cured” of the prion state. For example, Rnq1 is soluble 
and does not assemble into amyloid-like aggregates in strains that are cured of the [RNQ+] prion 
state; now designated [rnq-]. The cured strain can be compared back to the [RNQ+] strain to 
determine how cellular factors such as molecular chaperones interact with the soluble versus 
amyloidogenic conformer of the same protein. Yeast strains can be cured of the prion state by two 
methods. First, if the protein determinant is non-essential such as Rnq1 then deleting the RNQ1 gene 
will eventually cure yeast of the [RNQ+] prion state as the remaining Rnq1 protein is diluted over 
successive generations. If the Rnq1 protein is subsequently expressed in this strain from an exogenous 
plasmid, it will not assemble into amyloid-like aggregates because pre-existing [RNQ+] prion seeds 
are not present in the cell. An alternative and more common method is to treat cells with low doses of 
guanidine hydrochloride. This compound inhibits a molecular chaperone called Hsp104 that shears 
prion fibrils to generate new prion seeds and is required to propagate yeast prions (23,24). Two to 
three passages on solid media containing 3mM guanidine hydrochloride is typically sufficient to cure 
yeast of the prion state. One drawback to this method is that it is not selective for any specific prion. 
Both methods permanently cure yeast of the prion state because spontaneous prion induction is a 
highly unfavorable event (25). 
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3.4 Growth and viability assays 
Spotting Assay 
The most basic tool for studying amyloid toxicity in yeast is to monitor cell growth under 
conditions where an amyloidogenic protein is expressed compared to conditions when this protein 
either is not expressed or does not assemble into amyloid-like fibrils (ex. a cured prion strain). This 
method is readily applicable to high through-put screening of genetic factors that influence toxicity. 
Defects in cell growth can most easily be assessed by spotting yeast cells on solid agar media and 
comparing growth between strain expressing a toxic protein and a control strain. As shown in Figure 
3.1, expressing Rnq1 from the GAL1 promoter is toxic to yeast in a [RNQ+] dependent-manner (18). 
To perform this assay, single colonies from freshly transformed yeast are used to inoculate a liquid 
culture and when yeast cells have reach mid-log phase, equal concentrations of cells (~0.5 OD600) are 
serially diluted onto solid selective media containing 2% galactose as the carbon source and incubated 
for 2-4 days at 30°C depending upon the strain. As a control, strains are simultaneously spotted on 
selective media containing glucose to show that changes in growth rates are dependent upon 
expression of the aggregation-prone protein.  
Growth Curve 
 If differences in growth are too slight to detect by the spotting assay then toxicity can be 
quantitatively assessed by measuring growth curves in liquid media. The procedure begins as 
described above, except liquid cultures are induced with galactose at a very low density (OD600 0.01-
0.05) and OD600 measured approximately every 2 hours until strains reach stationary phase. 
Compared to the spotting assay, measuring growth curves is more labor intensive however this assay 
can determine at what point expression of a proteotoxic protein such as Rnq1 affects cell growth. 
Furthermore, resolving whether a defect in cell growth reflect cell cycle arrest or cell death might lead 
to a better understanding of the mechanism underlying proteotoxicity in this model system. To 
determine whether yeast cells have entered cell cycle arrest or cell death, an aliquot is removed from 
liquid cultures at varying timepoints post-expression and plated on selective media with 2% glucose 
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to repress the GAL1 promoter. If cell viability is indeed reduced upon protein expression, then yeast 
cells will not grow on media with glucose while yeast cells would be expected to reenter the cell 
cycle when the proteotoxic insult is removed.   
 
 
 
Figure 3.1. Expression of amyloid-forming proteins is toxic to yeast.  Yeast cells (strain BY4741-
[RNQ
+
] or [rnq-]) were transformed with an empty pRS416 vector or pRS416(GAL1-RNQ1). Liquid 
cultures were inoculated with freshly transformed yeast and incubated for one day at 30°C. Equal 
quantities of cells in mid-log phase (0.5 OD600) were serially diluted (1:5) onto selective media 
containing glucose or galactose and incubated for approximately 3 days at 30°C and photographed.  
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3.5 Morphological analysis of protein aggregation 
Fluorescence microscopy 
A rapid method to analyze protein aggregation is fluorescently-tagging a protein of interest 
and visualizing intracellular localization via fluorescence microscopy. For example, Rnq1-GFP forms 
punctuate structures in [RNQ+] cells while is predominantly diffuse in [rnq-] cells (Fig. 3.2). If 
tagged constructs are expressed from inducible promoters, then a time-course can be performed to 
determine the kinetics of aggregation. To freeze cells at specific timepoints, cells in mid-log phase are 
treated with 0.1M phosphate buffer (pH6.8) and 3.7% formaldehyde then incubated at 25°C for 30 
minutes to 1 hour. Cells are then washed once in phosphate buffer (pH7.4) and resuspended in 
phosphate buffer (pH 7.4) plus 1.2M sorbitol. Cells can be stored in this solution for several days at 
4°C and further processed for immunofluorescent detection of other proteins or stained with 
commercially available dyes to identify organelles. Alternatively, fluorophore-conjugated proteins 
can be visualized by live cell imaging to characterize the dynamics of protein aggregation on the 
order of seconds to minutes.  
There are several considerations when assessing protein aggregation by fluorescence 
microscopy. First, the appearance of foci within the cell does not imply the protein of interest is 
aggregating, yet may represent localization to a specific subcellular compartment or protein complex. 
Indeed, recent studies have suggested that misfolded and aggregated proteins are transported to 
distinct subcellular compartments (26), Thus, subcellular localization of a protein of interest should 
be compared with a panel of known organelle markers (ex nuclei, vacuole, etc).  Furthermore, 
intracellular foci might be disordered, amorphous aggregates rather than amyloid-like assemblies.  
Additional analysis using the methods described below need to be performed to determine whether 
intracellular foci are indeed amyloid-like fibrils.  
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Figure 3. 2. Visualization of protein aggregates by fluorescence microscopy. (A)BY4741 cells 
([RNQ
+
] or [rnq-]) in mid-log phase expressing Rnq1-GFP from the CUP1 promoter were induced 
with 50uM CuSO4 for 2 hours and live cells visualized with a FITC filter set.  
 
Thioflavin T Staining of Amyloid-like Fibrils in Yeast 
One of the classic, defining characteristics of  an amyloid-like fibril is recognition by 
amyloid-indicator dyes such as thioflavin T (27). Similar to amyloid fibrils formed in human diseases, 
intracellular yeast prion assemblies are also recognized by thioflavin T (18,28,29). To stain 
intracellular, amyloid-like particles with thioflavin T, an aggregation-prone protein such as Rnq1 is 
induced for an extended period of time (at least four hours) until it is predominantly assembled into 
single, distinct foci. Cells are fixed as described above, briefly permeabilized with phosphate buffer 
(pH 7.5) plus a weak non-ionic detergent such as 0.1% Triton-X, and treated with 0.001% thioflavin 
T for approximately 10 minutes at room temperature. The cells should be washed at least 3-4 times 
with phosphate buffer. Thioflavin T has excitation and emission wavelengths of 450nm and 482nm 
respectively when bound to amyloid-like fibrils and can be visualized in cells under standard FITC 
filter range. As a control [RNQ+] cells transformed with an empty vector can be used to determine 
the level of background staining and show thioflavin-t positive foci are dependent upon Rnq1 
overexpression. If background ThT staining is very high, then reducing the concentration of ThT or 
increasing the number of washes should alleviate this problem.  
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3.6. Biochemical analysis of amyloid-like aggregates 
The structure of amyloid-like aggregates renders these assemblies insoluble in ionic 
detergents such as sodium dodecyl sulfate (SDS). There are several assays that exploit this unique 
property to biochemically distinguish large, SDS-insoluble assemblies from unassembled, SDS-
soluble protein species in yeast cell extracts. As mentioned above, maintaining cells in mid-log phase 
is critical when performing these experiments. Additionally, if the aggregate-prone protein is 
expressed from an inducible promoter, a time-course experiment should be performed to characterize 
assembly kinetics.  Once the basic dynamics of protein assembly into SDS-resistant aggregates is 
established, then these assays can be performed under conditions where select cellular factors are 
overexpressed or deleted to determine how specific cellular pathways influence the assembly of 
amyloid-like aggregates.  
Differential high speed centrifugation 
 The most simple approach to characterizing the formation of amyloid-like aggregates is to 
separate SDS-insoluble aggregates by high speed centrifugation. This technique allows direct 
comparison between soluble and insoluble pools of an amyloid-forming protein. However, this 
technique is relatively insensitive to slight changes in the size of amyloid-like oligomers or fibrils. As 
shown in Figure 3.3A, excess Rnq1-YFP partitions predominantly in the SDS-insoluble fraction yet a 
pool also remains in the SDS-soluble supernatant. In contrast, excess Rnq1-YFP resolves exclusively 
in the SDS-soluble fraction in [rnq-] cells (18).  
To analyze solubility of Rnq1, cells expressing Rnq1 are first lysed by glass bead disruption 
under moderately denaturing conditions (150mM NaCl, Hepes pH7.4, 1mM EDTA, 1mM DTT, 1% 
Triton-X, 0.2% SDS, 1mM PMSF, protease inhibitor cocktail). Depending upon the amyloidogenic 
protein, the concentration of SDS can be increased to 2% to increase the stringency of this assay. Cell 
lysates are first processed by a short centrifugation step (650xg for 3min at 4°C) to remove unbroken 
cells.  After the spin, the supernatant is subsequently spun at 100,000 x g for 30min to 1 hour in 
1.5mL Beckman polyallomer centrifuge tubes.  The speed and time may vary depending upon the  
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Figure 3.3. Biochemical analysis of SDS-insoluble, amyoid-like aggregates. (A) Separation of 
SDS-insoluble Rnq1-GFP aggregates by high-speed differential centrifugation. BY4741 cells 
([RNQ
+
] or [rnq-] transformed with pGAL-RNQ1YFP were induced for 2 hours with 2% galactose. 
Cells were processed as described in the main text and equal volumes of total, supernatant, and pellet 
fractions were analyzed by SDS-PAGE and western immunoblotting for GFP (Roche) and Pgk1 
(Invitrogen). (B) SDD-AGE analysis of Rnq1-GFP SDS-insoluble aggregates. BY4741 cells ([RNQ
+
] 
or [rnq-] transformed with pCUP-RNQ1GFP were induced with 50uM CuSO4 and samples were 
collected at 0hr, 1hr, 2hr, and 4hr post-induction. Cells were processed as described in the main text 
and the PVDF membrane analyzed by western immunoblotting for GFP. Lysates were also analyzed 
by SDS-PAGE and western immunobloting for GFP (lower panel).  
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specific protein but these conditions appear sufficient for a majority of endogenous Rnq1 to resolve in 
the insoluble pellet in [RNQ+] cells. An aliquot from the lysate is saved prior to the spin represent the 
input (or Total) fraction. After the spin, an aliquot from the supernatant is saved and the pellet is 
resupended in lysis buffer (in a volume equivalent to the original volume used for the spin). Each 
fraction (total, supernatant, pellet) is mixed with a equal volume of 2X sample buffer (125mM Tris-
HCl pH6.8, 4% SDS, 4mM EDTA, and 20% glycerol, 8% beta-mercaptoethanol) and samples are 
analyzed by SDS-polyacrylamide gel electrophoresis (SDS-PAGE).  
Semi-denaturing detergent agarose gel electrophoresis (SDD-AGE) 
SDS-insoluble aggregates can also be separated from SDS-soluble protein species in an agarose 
gel. In contrast to methods that rely on SDS-PAGE, this method can resolve changes in the size of 
SDS-insoluble oligomers. For example, Kryndushkin et al  demonstrated that inhibiting the 
chaperone Hsp104 results in a transient increase in the size of SDS-insoluble oligomers and 
subsequent conversion into the SDS-soluble pool (30). This experiment provided crucial evidence 
that Hsp104 shears prion fibrils to generate new prion seeds in order to propagate the prion state. In 
Figure 3.3B, Rnq1-GFP was induced from a copper promoter and lysates from various timepoints 
resolved by SDD-AGE. As Rnq1-GFP accumulates, a SDS-insoluble pool appears first then a SDS-
soluble pool appears at the latest time point. However, Rnq1-GFP is entirely soluble in [rnq-] cells. 
Compared to differential high speed centrifugation, this technique is relatively more labor intensive, 
though it can provide significant insight into the relative ratio of soluble vs insoluble pools as well as 
changes in the size of SDS-insoluble oligomers. To perform this assay, yeast cells are lysed by glass 
bead disruption moderately denaturing conditions (150mM NaCl, 50mM Hepes pH 7.4, 1mM EDTA, 
1mM DTT, 1% Triton X, 0.2% SDS, 1mM PMSF, yeast protease inhibitor cocktail). Yeast lysates are 
cleared by centrifugation (650 x g, 3min, 4°C). The supernatant is saved and protein concentrations 
normalized between samples (higher concentrations are ideal >2.0mg/mL). Normalized lysates are 
added to an equal volume of 2X SDD-AGE buffer (1XTAE buffer [0.8mM Tris-Acetate,0 .02mM 
EDTA], 4% SDS, 10% glycerol 8% beta-mercaptoethanol). Lysates are incubated at 37°C for 10 
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minutes and at least 100μg loaded into a 1.5% agarose gel (made with 1xTAE buffer + 0.1%SDS). 
Lysates are run at ~70 volts for approximately 2-3 hours. The gel is transferred  onto a PVDF 
membrane at 24 volts for 1.5 hours in standard Tris-based buffer (alternatively you can transfer for 8 
hours at 12 volts).The transfer step generates a large amount of heat so the buffer and transfer 
apparatus should be chilled at 4°C prior to use. The transfer step is inefficient and requires practice 
and some optimization. The PVDF membrane is analyzed by western immunoblotting for the protein 
of interest using standard methods.  
Filter Trap 
A filter trap assay is another common and rapid method for analyzing the formation of large, 
SDS-insoluble aggregates. Initially, this technique was used to analyze aggregation of the 
polyglutamine-expanded form of huntingtin from cell and tissue extracts (31). However, this assay 
can also be applied to the analysis of large, SDS-insoluble aggregates formed by yeast prions (32,33). 
In contrast to the assays described above only the large, SDS-insoluble pool is observed and cannot 
be directly compared to the SDS-soluble pool that is lost through the cellulose acetate membrane. 
However, this technique is applicable to large scale analysis, for example, assessing changes in SDS-
insoluble aggregate formation under a variety of environmental conditions or genetic backgrounds.  
To perform this assay, yeast lysates are generated as described above for SDD-AGE analysis. 
After protein concentrations are standardized between samples, lysates are applied to a cellulose 
acetate membrane (0.2μM pore size -Beckman) that is previously equilibrated with lysis buffer and 
assembled in a slot blot apparatus. The samples are allowed to flow through the membrane by gravity. 
While still in the slot blot apparatus, the membrane is washed with lysis buffer containing 2% SDS. 
Once the membrane is dry, it is subsequently processed by western immunoblotting for the protein of 
interest.  Samples should also be spotted onto a nitrocellulose membrane or analyzed by SDS-PAGE 
to analyze total protein levels.  If there is a high level of background, then the concentration of SDS 
can be increased or the samples heated at various temperatures prior to application on the membrane.  
Alternatively, the samples can be titrated onto the membrane to identify the linear range of the signal. 
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If there is a poor signal, then the amount of SDS can be reduced or the protein induction time 
increased to accumulate more of the SDS-insoluble aggregate pool.  
Size-exclusion chromatography 
The assays described above separate amyloid-like particles into a SDS-soluble and SDS-
insoluble protein species. However, there are times when more detailed resolution is required to 
characterize assembly intermediates that are solubilized by the presence of SDS.  In addition, protein-
protein interactions are typically disrupted by the presence of SDS and lost in these assays. To bypass 
this complication, amyloid-like assemblies can be resolved by size exclusion chromatography. We 
have previously used this technique to distinguish the ratio of assembled, high molecular weight 
pools of Rnq1 from unassembled, low molecular protein species  (22,32,33). Resolving yeast cell 
extracts by size-exclusion chromatography requires a large quantity of yeast (>100 OD600) because 
cell extracts are diluted over the column volume which can exceed 100mL depending upon the 
specific column. Cell growth conditions are the same was described above with a particular emphasis 
on maintaining cells in mid-log phase and proper aeration throughout the experiment especially as the 
culture volume is expanded to liter-size to collect enough yeast cells for this experiment.  Cells  are 
lysed as described above by glass bead disruption in non-denaturing lysis buffer (150mM NaCl, 
50mM Hepes pH 7.4, 1mM EDTA, 0.1% Triton X, plus  1mM PMSF  and protease inhibitor 
cocktail). Specific components in this buffer can be modified depending upon the protein-protein 
interactions that are under investigation. For example, if a specific protein-protein interaction is ATP-
dependent, then EDTA should be omitted and ATP included in the buffer. Cell lysates are precleared 
twice by centrifugation (650 x g, 3min, 4°C) to ensure cell debris is completely removed from the 
lysate.  Inject about 1-5mg cell lysate into size-exclusion column (pre-equilibrated with cold lysis 
buffer) and collect fractions spanning the void volume to the fractions eluting with the molecular 
weight of the monomer. The void volume is typically identified by the elution volume of blue dextran 
and the included volume of the column calibrated by a series of known molecular weight markers. 
Fractions can be assessed for proteins of interest by SDS-PAGE and western immunoblotting.  
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If lysates are separated on the appropriate resin then the relative ratio of assembled to 
unassembled protein can be directly compared. One important consideration is that this approach does 
not distinguish SDS-insoluble, amyloid-like particles from disordered aggregates or large protein 
complexes because denaturing buffers are not always compatible with resins in size-exclusion 
columns. To overcome this restriction, elution fractions can be applied to the assays described above 
to identify fractions that contain SDS-insoluble aggregates. Furthermore, the elution profile of Rnq1 
in a [RNQ+] strain can be compared back to the elution profile in a [rnq-] strain when these proteins 
do not assemble into amyloid-like conformers (17,18,32). 
In summary, these biochemical assays offer distinct methods for analyzing the assembly of 
amyloid-like aggregates. Differential centrifugation and filter trap are the least labor techniques yet 
do not reveal insight on aggregate size and are most insensitive to subtle changes in the levels of 
SDS-insoluble aggregates. In contrast, SDD-AGE and size exclusion chromatography are more labor 
intensive and provide more sensitive information on aggregate assembly such as relative oligomer 
size. Finally, while size exclusion chromatography does not distinguish SDS-soluble from SDS-
insoluble aggregates, it is the most sensitive method for separating aggregates based on oligomer size 
and allows for identification of protein:protein interactions that are lost during solubilization in SDS. 
A comprehensive approach (using methods from both categories) is ideal when trying to understand 
how cellular factors such as molecular chaperones influence amyloid assembly pathways and 
proteotoxicity.  
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3.7. Final Conclusions 
The connection between amyloid fibril formation and neurodegeneration is a significant 
matter of debate. Despite enormous effort over several decades, our basic understanding of the 
amyloid assembly pathway is still lacking and the complex interplay between protein quality control 
networks and protein aggregation remains unclear. Budding yeast has emerged as a powerful model 
system to investigate mechanistic details underlying how assembly of amyloid-like aggregates 
contributes to cell death. A wide variety of cellular assays are available to dissect this problem 
utilizing the power of yeast genetics as well as biochemical manipulation of yeast extracts. While 
yeast cells cannot recapitulate every feature specific to neurons studies in S. cerevisiae can provide a 
sound foundation of mechanistic understanding to test specific hypothesizes in more complex model 
organisms.   
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Chapter Four 
The type I Hsp40 Ydj1 utilizes a farnesyl moiety and zinc finger-like region to suppress prion 
toxicity 
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4.1 Abstract 
 Type I Hsp40s are molecular chaperones that protect neurons from degeneration by 
modulating the aggregation state of amyloid-forming proteins. How Type I Hsp40s recognize -
rich, amyloid-like substrates is currently unknown. Thus, we examined the mechanism for 
binding between the Type I Hsp40 Ydj1 and the yeast prion [RNQ
+
]. Ydj1 recognized the 
Gln/Asn-rich prion domain from Rnq1 specifically when it assembled into the amyloid-like 
[RNQ
+
] prion state. Upon deletion of YDJ1, overexpression of the Rnq1 prion domain killed 
yeast. Surprisingly, binding and suppression of prion domain toxicity by Ydj1 was dependent 
upon farnesylation of its C-terminal CAAX box and action of a zinc-finger-like region. In 
contrast, folding of luciferase was independent of farnesylation, yet required Ydj1's zinc finger-
like region and a conserved hydrophobic peptide-binding pocket. Type I Hsp40s contain at least 
three different domains that that work in concert to bind different protein conformers. The 
combined action of a farnesyl moiety and zinc finger-like region enable Type I Hsp40s to 
recognize amyloid-like substrates and prevent formation of cytotoxic protein species. 
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4.2 Introduction 
 Protein misfolding and aggregation are common themes in neurodegenerative maladies 
termed conformational diseases. A subset of these disorders including Alzheimer’s disease and 
the transmissible spongiform encephalopathies (prion diseases) are characterized by the 
accumulation of a stable, ß-sheet rich fibrils called amyloid (1). Criteria that distinguish amyloid-
like fibrils from amorphous aggregates include resistance to SDS-solubilization and binding of 
the dye thioflavin T (2). The direct connection between amyloid accumulation and 
neuropathology is still a matter of debate (3-5).  Yet, the flux of proteins through amyloid 
forming pathways correlates well with disease (3-5).  
 Hsp70 molecular chaperones protect against neurodegeneration associated with 
conformational disease via suppression of protein aggregation or conversion of toxic species into 
non-toxic aggregates or amyloid (6,7). Hsp70 has broad substrate selectivity and co-chaperones in 
the Hsp40/DnaJ family specify Hsp70 targets. Upon delivery of substrate, Hsp40s stimulate 
Hsp70 ATPase activity through a conserved J-domain and thereby stabilize Hsp70:polypeptide 
complexes. Nucleotide exchange factors (NEFs) convert Hsp70-ADP to Hsp70-ATP releasing 
non-native substrate for further rounds of folding or degradation (8,9). Escape of disease-related 
proteins from the action of Hsp70/Hsp40 and other quality control machinery leads to the 
accumulation of toxic protein species (10). 
 Recognition of pathogenic proteins by Hsp40s represents an important line of defense against 
the accumulation of cytotoxic protein species (4,11). However, the mechanism for substrate 
recognition by Hsp40s is unclear because the Hsp40 family is large and members have 
specialized domains that direct them to different subcellular locations or enable binding to select 
substrates (12,13). Type I Hsp40s possess a centrally located domain, which contains a zinc-
finger like region (ZFLR), that appears to control the quaternary structure of Type I Hsp40 
homodimers (14). The ZFLR has been implicated in substrate transfer to Hsp70 and the binding 
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of some Type I Hsp40 substrates (15-17). Type I Hsp40s can independently bind non-native 
polypeptides and also cooperate with Hsp70 to suppress protein aggregation (18,19). Importantly, 
human and yeast Type I Hsp40s are highly conserved and functionally interchangeable (12). 
 Interestingly, Type I Hsp40s such as human DnaJ 2 (HDJ-2) and yeast DnaJ 1 (Ydj1) are 
unique in that they contain a C-terminal CAAX box that is post-translationally modified by 
farnesyl (20,21). Farnesylation helps localize a pool of Type I Hsp40s to the cytoplasmic face of 
the endoplasmic reticulum (ER) and is required for cells to survive heat stress (22). One function 
of ER-localized Type I Hsp40s is the folding of polytopic membrane proteins (21). However, 
even though the entire pool of Ydj1 is farnesylated a large portion is found in the cytosol (22). 
Thus, it is conceivable that the farnesyl moiety of Ydj1/Hdj-2 has additional roles in 
cytoprotection including regulation of stress response or assistance with polypeptide binding. 
 Study of Hsp40 action in propagation of the yeast prion [RNQ
+
]/[PIN
+
] (23,24) provides a 
tractable model system to answer basic questions about mechanisms for chaperone action in the 
suppression of proteotoxicity. Overexpression of Rnq1 kills yeast in the presence of [RNQ
+
] 
seeds, yet toxicity is associated with the accumulation of off-pathway, non-amyloid forms of 
Rnq1 (4). Rnq1 has an N-terminal non-prion domain with no known enzymatic function though it 
appears to regulate the conversion of native Rnq1 into the [RNQ
+
] prion (25). Rnq1 also 
possesses a C-terminal prion domain (PrD) that is enriched in glutamines (Gln) and asparagines 
(Asn) and readily assembles into the [RNQ
+
] prion state when expressed alone or as a chimera 
(23,26). Interestingly, the Type II Hsp40 Sis1 is required for [RNQ
+
] propagation (27) and 
suppresses Rnq1 toxicity via increasing the flux of Rnq1 into the [RNQ
+
] assembly pathway (4). 
On the other hand, the Type I Hsp40 Ydj1 can cure yeast of some [RNQ
+
] variants (28), but it 
cannot suppress Rnq1 cytotoxicity (4). While Sis1 binds a hydrophobic motif in the Rnq1 non-
prion domain (4) the Ydj1-binding site is unknown (29). Since Ydj1 and Sis1 show distinct 
substrate selectivity (13) we investigated whether they exert their disparate effects on Rnq1 
biogenesis and toxicity via binding different Rnq1 domains. 
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 We found that purified Ydj1 recognizes Gln/Asn-rich peptides in the PrD of Rnq1. In in vivo 
studies, Ydj1 specifically recognized the amyloid-like [RNQ
+
] form of the Gln/Asn-rich Rnq1 
PrD. Furthermore, deletion of YDJ1 sensitized yeast to excess levels of the PrD. Interestingly, 
Ydj1 binding and suppression of toxicity was dependent upon both the Type I Hsp40 ZFLR and 
farnesylation. On the other hand, the ZFLR and peptide-binding pocket cooperated in the folding 
of luciferase, while farnesylation of Ydj1 was dispensable in this activity. Thus, Type I Hsp40s 
utilize specialized domains to recognize non-native proteins that exist in different conformational 
states. Demonstration of the domain requirements for Ydj1 binding to the amyloid-like conformer 
of the Rnq1 helps explain how human Type I Hsp40s fight conformational disease. 
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4.3 Results 
 The Rnq1 PrD forms benign intracellular aggregates. Overexpression of Rnq1 is toxic to 
yeast when endogenous Rnq1 is assembled in its [RNQ
+
] conformation (4). Cell death is thought 
to occur due to inefficient conversion of overexpressed Rnq1 into amyloid-like [RNQ
+
] prions 
and the accumulation of a templated toxic species. Furthermore, defects in Sis1-binding 
exacerbate Rnq1 toxicity by decreasing the efficiency of [RNQ
+
] assembly. The nature of the 
toxic Rnq1 species is not clear and how defects in chaperone binding lead to its accumulation are 
unknown. Thus, we investigated whether removal of the entire non-prion domain and elimination 
of the Sis1 binding site would enhance Rnq1 proteotoxicity. However, while overexpression of 
Rnq1 was toxic to [RNQ
+
] cells, overexpression of the PrD was not (Fig. 4.1A & B). 
Overexpression of Rnq1 or PrD did not alter cell growth in the absence of prion seeds ([rnq-] 
background). Thus, the presence of the non-prion domain on Rnq1 somehow leads to the 
accumulation of a toxic Rnq1 species.To gain insight into the nature of the toxic Rnq1 species we 
characterized intermediates on the pathway for conversion of native Rnq1 and PrD into amyloid-
like [RNQ
+
] prion. Rnq1-GFP and PrD-GFP each formed intracellular aggregates in a [RNQ
+
] 
background that were morphologically indistinguishable by fluorescence microscopy (Fig. 4.1C). 
Rnq1 was not observed to coalesce in a [rnq-] background though a small population of cells 
(<5%) expressing PrD-GFP contained non-toxic aggregates. In a [RNQ
+
] background, Rnq1-GFP 
partitioned predominantly in the Triton-insoluble pellet of yeast extracts, though a significant 
population was present in the Triton-soluble supernatant (Fig. 4.1D). In contrast, PrD-GFP 
fractionated exclusively in the Triton-insoluble pellet in a [RNQ
+
] background. In a [rnq-] state, 
Rnq1-GFP was predominantly soluble while PrD-GFP was present in both Triton-soluble and 
insoluble appear toxic.  
 Next, the size of Rnq1-GFP and PrD-GFP assembly intermediates was examined by gel 
filtration chromatography (Fig. 4.1E). In [RNQ
+
] cells, Rnq1-GFP eluted in two distinct high 
molecular pools; one near the void volume (Vo) and the other in a broad peak that was larger than  
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Figure 4.1 The Rnq1 PrD assembles into benign [RNQ
+
] prion. (A) Domain boundaries of 
Rnq1 from S. cerevisiae. (B) Wild type yeast in a [RNQ
+
] or [rnq
-
] background harboring 
galactose-inducible forms of Rnq1, PrD, or an empty vector were serially diluted onto media 
containing galactose or glucose. Western blots below show protein levels. (C) Fluorescence 
microscopy of representative cells expressing Rnq1-GFP or PrD-GFP in a [RNQ
+
] or [rnq
-
] 
background. (D) Differential centrifugation of Rnq1-GFP and PrD-GFP in a [RNQ
+
] or [rnq
-
] 
background. Briefly, cell lysates were generated under non-denaturing conditions (50mM Hepes 
pH 7.4, 150mM NaCl, 0.1% Triton X-100, 1mM EDTA) and separated by high-speed 
centrifugation (100,000xg). Total input (T), supernatant (S), and pellet (P) fractions were resolved 
by SDS-PAGE. (E) Yeast lysates generated as above under non-denaturing conditions were 
resolved on a Sephacryl S-500HR gel filtration column. Every other fraction was examined by 
SDS-PAGE. Below is quantification of fractions normalized to total signal from [RNQ
+
] lysates 
(left graph) or [rnq-] lysates (right graph). 
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Figure 4.2 The Rnq1 PrD forms SDS-insoluble, amyloid-like [RNQ
+
] prion. (A) In wildtype 
cells, PrD-RFP was expressed overnight from a copper inducible promoter in [RNQ
+
] and [rnq
-
] 
cells. Cells were fixed and permeabilized then treated with the amyloid indicator dye Thioflavin t. 
Arrows indicate PrD-RFP aggregates that co-localized with thioflavin T positive puncta. 
Thioflavin T staining was diffuse in [rnq
-
] background. As a control, [RNQ
+
] cells harboring an 
empty vector were treated simultaneously to demonstrate Thioflavin t positive puncta were 
dependent upon PrD-RFP expression and did not represent amyloid-like aggregates from other 
yeast prions. (B) PrD-GFP was expressed in wild type cells in a [RNQ
+
] and [rnq
-
] background 
and cell lysates subjected to SDD-AGE analysis. PrD-GFP formed SDS-insoluble only observed 
in [RNQ
+
] cells. (C) PrD-GFP assembly into SDS-insoluble aggregates was also assessed by filter 
trap. Cell lysates were analyzed during a time course for retention on a cellulose acetate 
membrane under denaturing conditions. PrD-GFP only formed SDS-insoluble aggregates in 
[RNQ
+
] cells. 
62 
 
thyroglobulin (669kDa), but still in the included volume. In addition, a pool of Rnq1-GFP eluted 
similar to a monomeric form. PrD-GFP also formed two high molecular weight pools, yet in 
contrast to Rnq1; no low molecular weight species was detected. The material in the void volume 
was predominantly SDS-soluble while Rnq1/PrD-GFP species in the broad included peak were 
insoluble in SDS (data not shown). In a [rnq-] background, Rnq1-GFP resided exclusively in the 
low molecular weight pool while PrD-GFP eluted in the void volume as well as a low molecular 
weight pool (Fig. 4.1E). 
 These observations suggest deletion of the non-prion domain predisposes the PrD to 
spontaneous aggregation in either a [RNQ
+
] or [rnq-] background. However, PrD aggregates in a 
[rnq-] background are not amyloid-like because the PrD only forms thioflavin T-positive, SDS-
resistant aggregates in a [RNQ
+
] background (Fig. 4.2). Thus, the presence of the non-prion 
domain predisposes a small portion of Rnq1 to accumulate in a soluble pool, which could result 
from inefficient assembly or increased shearing of [RNQ
+
] prions into [RNQ
+
] seeds by Hsp104 
(27). Observations that PrD overexpression is not toxic and it's assembly into amyloid-like prions 
is not accompanied by the accumulation of a soluble PrD pool supports the notion that 
accumulation of soluble Rnq1 in a [RNQ
+
] background leads to death (4). 
Ydj1 binds the Gln/Asn-rich PrD in its [RNQ
+
] conformation. Deletion of the Rnq1 non-
prion domain and the Sis1-binding motif (4), renders the PrD prone to form benign aggregates in 
[RNQ
+
] and [rnq-] cells. The combined ability of the cell to package the PrD into amyloid-like 
assemblies as well as SDS-sensitive aggregates may account for the benign consequences of PrD 
overexpression. Chaperones facilitate the formation of benign, non-amyloid aggregates of A1-42 
(30). Therefore, we speculated that an Hsp40 other than Sis1 may recognize the Gln/Asn-rich PrD 
and prevent the formation of a toxic PrD species by facilitating the conversion of soluble, 
unassembled PrD species into benign SDS-sensitive aggregates. 
 The Type I Hsp40 Ydj1 binds Rnq1 (29), so it may modulate PrD assembly. To identify the 
Ydj1 binding site in Rnq1, we screened a Rnq1 peptide array with purified Ydj1 (Fig. 4.3A & B).  
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Figure 4.3 Ydj1 interacts with the PrD of Rnq1. (A) Rnq1 amino acid sequence from S. 
cerevisiae. Residues in the PrD of Rnq1 are highlighted. (B) A 25 amino acid peptide array from 
Rnq1 was screened with purified Ydj1. Peptides bound by Ydj1 are highlighted. The intensity of 
the highlight designates relative binding as assessed by immunoblotting for Ydj1. Three sample 
peptides from the PrD that were recognized by Ydj1 are listed below. (C) Rnq1-GFP or PrD-GFP 
were expressed in wild type yeast in a [RNQ
+
] or [rnq
-
] background and cell lysates generated 
under non-denaturing conditions. Ydj1 was co-immunoprecipitated and bound Rnq1-GFP or PrD-
GFP was assessed by western immunoblotting for GFP (right panel). The same lysates were 
incubated in the absence of Ydj1 antisera to show background binding to Protein G beads (-ab). 
Expression levels from whole cell lysates represent 10% input (left panel). 
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Each peptide in the array was 25 amino acids in length and shared 22 amino acids with the 
adjacent peptide such that small binding motifs could be identified. Ydj1 bound numerous 
peptides from the PrD, but no peptides from the non-prion domain (Fig. 2.3B). Ydj1 bound 
peptides that were typically composed of Gln/Asn-rich motifs interrupted by aliphatic or aromatic 
residues (Fig. 4.3B). These hydrophobic residues may facilitate binding with the Ydj1 
hydrophobic peptide-binding pocket (31). Consistent with this possibility, Ydj1 did not bind a 
glutamine/glycine repeat at the beginning of the PrD. However, numerous hydrophobic residues 
are present in the non-prion domain and the terminal 50 amino acids of Rnq1 that were not bound 
by Ydj1. As such, the arrangement of Gln and Asn amino acids along with hydrophobic residues 
appears critical for Ydj1 to specifically recognize PrD peptides. 
 Ydj1 binds proteins with polyglutamine repeats in a manner that is dependent upon the 
expansion length and regulates their assembly into higher order aggregates (32,33). Thus, Ydj1 
may be able to recognize substrates enriched in b-structure. To address whether conversion of 
Rnq1 or the PrD into a b-rich conformation is required for Ydj1 binding, we assessed Ydj1’s 
interaction with the native or amyloid-like prion forms of Rnq1 and the PrD. Ydj1 co-
immunoprecipitated Rnq1-GFP and PrD-GFP from [RNQ
+
] lysates, yet not from [rnq-] lysates 
suggesting Ydj1 prefers the [RNQ
+
] prion conformation of these proteins (Fig. 4.3C). In addition, 
Ydj1 did not co-immunoprecipitate the non-prion domain alone and the PrD was a poor substrate 
for Sis1 in [RNQ
+
] lysates (Fig. 4.4). The PrD from Rnq1 assembles into thioflavin T-positive, 
amyloid-like fibrils (34,35). Therefore Ydj1, but not Sis1, recognizes the PrD of Rnq1 in its -
sheet rich, amyloid-like conformation. 
Overexpressing the PrD is toxic to yeast in the absence of YDJ1. If Ydj1 binds the PrD in its 
amyloid-like conformation, then Ydj1 may act analogous to Sis1 in suppressing Rnq1 toxicity by 
facilitating assembly of the PrD into a benign conformation. To test this hypothesis, the PrD was 
overexpressed in a ydj1 strain that contains pre-existing [RNQ+] prions. Indeed, PrD 
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Figure 4.4 Ydj1 specifically binds the PrD of Rnq1. (A) Ydj1 co-immunoprecipitated Rnq1-
YFP, PrD-YFP, yet not NPrD-YFP from [RNQ
+
] lysates (right panel). Protein levels are shown in 
the left panel. Binding was assessed by western immunoblotting for GFP. (B) Sis1 interaction 
with the PrD is reduced compared to full length Rnq1. Rnq1-GFP and PrD-GFP were expressed 
in yeast from a [RNQ
+
] background  and endogenous Sis1 co-immunoprecipitated from lysates 
with Sis1 antisera or a pre-immune control. Binding between Sis1 and Rnq1-GFP or PrD-GFP 
was assessed by western immunoblotting for GFP. 
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Figure 4.5 Deletion of YDJ1 sensitizes yeast to overexpression of the PrD. (A) Cells in a 
ydj1 strain ([RNQ+] background) were transformed with an empty pRS315 plasmid or a pRS315 
plasmid expressing Ydj1 from the YDJ1 promoter. These strains were further transformed with 
plasmids harboring galactose-inducible PrD or empty plasmid (pRS416). These cells were 
serially diluted onto selective media containing galactose or glucose. Western blots below show 
protein expression levels. (B) Fluorescence microscopy of representative cells expressing PrD-
GFP in the presence or absence of Ydj1. (C) Differential centrifugation as performed in Figure 1 
of cell lysates from strains expressing PrD-GFP in the presence or absence of Ydj1 [right panel: 
supernatant (S) and pellet (P)]. Left panel shows protein levels from whole cell lysates. (D) Gel 
filtration analysis of PrD-GFP in the presence or absence of Ydj1 as in Figure 1. Fractions from a 
YDJ1-rescued strain were also assessed for Ydj1 distribution. Below is quantification of PrD-GFP 
levels in every other fraction normalized to total PrD-GFP. (E) The assembly of SDS-resistant 
PrD-GFP was determined by filter trap analysis. PrD-GFP was induced in the presence or  
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overexpression was highly toxic to yeast in a ydj1 background (Fig. 4.5A). Cell viability was 
rescued by Ydj1 expression from a low copy plasmid from its own promoter. Even though PrD 
expression from the GAL1 promoter was toxic, PrD protein levels were much lower in the ydj1 
strain compared to the YDJ1-rescued strain (Fig 4.5A; lower panel). This was not surprising  
because YDJ1 is required for efficient nucleosomal remodeling that is required for activation of 
the GAL1 promoter (36).  
 In contrast to what is observed with [RNQ
+
] assembly when Sis1 is depleted (4,27), the PrD 
still formed intracellular aggregates and did not accumulate as a soluble species when Ydj1 was 
deleted (Fig. 4.5B-D) In fact, the only difference we observed was a close to 2-fold increase in 
the levels of SDS-resistant PrD-GFP in the ydj1 strain compared to wild type background (Fig. 
4.5E). Therefore, Ydj1 appears to enable yeast to tolerate PrD expression by limiting the pool of 
amyloid-like PrD assemblies. Consistent with this hypothesis, overexpression of Ydj1 decreased 
the level SDS-resistant PrD-GFP (Fig. 4.5F). Thus, PrD toxicity appears to differ from Rnq1 
toxicity in that the accumulation of SDS-resistant forms of PrD, and not a low molecular weight, 
detergent-soluble species correlates with cell death.  
 The mechanism via which Ydj1 modulates the accumulation of SDS-resistant PrD and 
suppresses PrD toxicity is unclear. Ydj1 may cap the exposed ends of elongating PrD amyloid or 
interact with Hsp104 (37) to maintain the level of this species within a tolerable range. 
Alternatively, Ydj1 may coat PrD particles to prevent non-specific protein:protein interactions 
that titrate essential cellular factors. We favor the former model because while Ydj1 co- 
Figure 4.5 cont . . .absence of Ydj1 and cells were lysed under denaturing conditions (2% SDS, 
62.5mM Tris-HCl pH6.8, 1mM EDTA, 5% glycerol, 2% -mercaptoethanol). Lysates were 
applied to a cellulose acetate filter and retained PrD-GFP was assessed by western 
immunoblotting for GFP. (F) Levels of SDS-resistant PrD-GFP were also determined in the 
presence of overexpressed Ydj1. Wild type yeast harboring an empty vector (pRS315) or YDJ1 
under the control of a constitutively active promoter (GPD) expressing PrD-GFP were lysed as 
described in (E) and lysates analyzed by filter trap. Panels below show protein levels from cell 
lysates used in filter trap assay. 
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Figure 4.6 The Ydj1 CAAX box is required to suppress PrD toxicity. (A) Domain structure of 
Ydj1 and truncations used in this study. (B) Truncations and mutants were expressed in a pRS315 
(low copy) plasmid under control of the YDJ1 promoter in a ydj1 background. These cells, 
harboring a plasmid expressing the PrD on a galactose-inducible promoter, were serially diluted 
onto media containing galactose and grown at 30C. These cells were also serially diluted onto 
media containing glucose and grown at 30C or 33C. (C) Binding between Ydj1 or 
Ydj1(C406S) with PrD-GFP was assessed by co-immunoprecipitation with Ydj1 antisera. PrD-
GFP levels in the ydj1 strain (pRS315) represent background binding to the Protein G beads. 
Percentages below represent bound PrD-GFP levels as a percentage of wild type Ydj1 normalized 
to background. (D) SDS-resistant PrD-GFP was compared in a ydj1, Ydj1, or Ydj1(C406S) 
background by filter trap. Panels below show protein levels from cell lysates. 
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immunoprecipitates with PrD-GFP we did not observe a large pool of Ydj1 co-migrating with 
PrD-GFP on gel filtration columns. Instead, Ydj1 eluted in a broad peak higher than the predicted 
molecular weight for a Ydj1 homodimer (~90kD). This may occur because Ydj1 forms 
complexes with an array of different cellular proteins. In addition, Ydj1 is farnesylated and this 
post-translational modification may lead it to behave like a protein with a higher molecular 
weight in gel filtration analysis. Nevertheless, only a small pool of Ydj1 binds and co-migrates 
with PrD prions and this does not seem sufficient to serve a coating function.  
 Mutation of the CAAX box prevents Ydj1 from suppressing PrD toxicity. The ability of 
Ydj1 to specifically recognize the Gln/Asn-rich PrD was surprising because numerous studies 
suggest Type I Hsp40s prefer peptides enriched in hydrophobic amino acids (13,38). Thus, we 
investigated the structural features in Ydj1 that enable it to bind and modulate PrD toxicity. First, 
we demonstrated that Sis1 could not suppress the toxicity observed when PrD was overexpressed 
and the ydj1 strain (data not shown). Then we sought to define the minimal length of Ydj1 
required to suppress PrD toxicity (Fig. 4.6A). The ydj1 strain normally exhibits a slow growth 
phenotype (20) and  the Ydj1 J-domain and G/F-rich region can restore normal growth in a ydj1 
strain (39). Yet, this same Ydj1 fragment could not suppress PrD toxicity (Fig. 4.6B). While the 
Ydj1 J-domain was not sufficient to suppress PrD toxicity, an active J-domain was still necessary 
because mutation in the conserved HPD tripeptide motif (H34Q) that severely disrupts interaction 
between Ydj1 and Hsp70 (40) rendered yeast unable to tolerate PrD toxicity (Fig. 4.7A). Binding 
between PrD-GFP and Ydj1(H34Q) was only slightly reduced (74% of wild type) and the levels 
of SDS-resistant PrD-GFP were increased with Ydj1(H34Q) compared to wild type (Fig 2.7B & 
C). Altogether, these observations suggest functional features of Ydj1 that support normal growth 
are less complex than those required to suppress PrD toxicity.  
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Figure 4.7 A functional J-domain is required for Ydj1 to suppress PrD toxicity. (A) Cells in 
a ydj1, Ydj1 (wild type), or Ydj1(H34Q) background harboring PrD on a galactose-inducible 
promoter were serially diluted onto media containing galactose or glucose. (B) Binding between 
PrD-GFP and Ydj1(wild type) and Ydj1(H34Q) was assessed by co-immunoprecipitation with 
Ydj1 antisera. Percentages below represent bound PrD-GFP levels as a percentage of wild type 
YDJ1 normalized to background (ydj1). (C) SDS-insoluble PrD-GFP levels was compared 
between ydj1, Ydj1(wild type), Ydj1 (H34Q) by filter trap. The panel below shows protein 
expression levels from lysates used in the filter trap assay.  
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 Ydj1(1-336) contains the J-domain, G/F-rich region, ZFLR, and a polypeptide-binding 
pocket, yet the Ydj1 dimerization domain is severed (41) and a CAAX motif required for 
farnesylation is missing (22). Ydj1 fragments with similar domain structures bind non-native 
polypeptides and suppress protein aggregation (42). Expression of Ydj1(1-336) in the ydj1 
strain restored normal growth, but barely protected against PrD toxicity (Fig. 4.6B). To determine 
whether dimerization and/or farnesylation are required for complete suppression of PrD toxicity, 
specific point mutants in the extreme Ydj1 C-terminus were examined. Ydj1(F335D), which 
contains point mutation in the dimerization domain that monomerizes Ydj1 (data not shown)(41), 
suppressed PrD toxicity as well as wild type suggesting the Ydj1 monomer is sufficient in this 
activity. However, mutation of the CAAX box (C406S) eliminated Ydj1’s ability to suppress PrD 
toxicity (Fig. 4.6B). 
 These data were surprising because farnesylation is thought to be required for membrane 
localization of Ydj1 yet PrD prions appear cytosolic. Thus, we investigated whether farnesylation 
is required for Ydj1 to bind the amyloid-like form of the PrD. Indeed, we observed an 80% 
reduction in complex formation between Ydj1(C406S) and the PrD (Fig. 4.6C). However, the 
pool of SDS-insoluble PrD-GFP was not increased with Ydj1(C406S) compared to wild type 
(Fig. 4.6D). The residual binding between Ydj1(C406S) and the PrD may be sufficient to control 
the accumulation of SDS-insoluble aggregates: though farnesylation of Ydj1 was clearly required 
for tolerance of PrD overexpression.  
 To demonstrate that defects in Ydj1 (C406S) function were indeed due to the lack 
farnesylation, the PrD was expressed in a ram1 strain, in which a non-essential 
farnesyltransferase subunit was deleted. In this strain background Ydj1 is not farnesylated (44) 
and overexpression of the PrD is toxic (Fig. 4.8). In addition, interactions between Ydj1 and the 
PrD in the ram1 strain were reduced. Thus, defects in the ability of Ydj1(C406S) to suppress 
PrD toxicity are indeed due to loss of farnesylation. These data provide the first evidence for a  
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 Figure 4.8 Deletion of the farnesyltransferase subunit RAM1 disrupts binding to PrD-GFP. 
(A) Cells deleted for YDJ1 were transformed with a pRS315 empty vector (ydj1), wild type 
Ydj1 or Ydj1 (C406S). A ram1 strain was also transformed with a pRS315 empty vector. These 
strains harboring an empty pRS416 vector (-) or pGAL PrD (+) were serially diluted onto 
selective media containing glucose or galactose and grown for 3 days at 30C. The PrD was toxic 
in the ydj1, Ydj1(C406S) and ram1 background. (B) Ydj1 was co-immunoprecipitated from 
cell lysates expressing PrD-GFP from a copper promoter as described in the main text. Bound 
PrD-GFP was assessed by western immunoblotting for GFP. Note that Ydj1(C406S) and 
endogenous Ydj1 in a ram1 strain display reduced mobility by SDS-PAGE demonstrating that 
Ydj1 is not farnesylated in the ram1 background. Binding between PrD-GFP and Ydj1(C406S) 
as well as endogenous Ydj1 in the ram1 strain was reduced. (C) The assembly of SDS-resistant 
PrD-GFP was determined by filter trap as described in the main text. The level of SDS-resistant 
PrD-GFP is elevated in a ydj1 compared to the wild type Ydj1 background. However, no 
increase is observed in the Ydj1(C406S) or ram1 background. These observations demonstrate 
that farnesylation of Ydj1 is required for efficient binding to PrD-GFP.  
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role of a farnesyl moiety on a Type I Hsp40 in binding to an amyloid-like substrate and in 
suppression of prion toxicity. 
The ZFLR is required to bind the PrD and suppress toxicity.  
 Since Ydj1(C406S) could still control levels of amyloid-like PrD prions, we explored the role 
for the Type I Hsp40 ZFLR (17,31) in complex formation between Ydj1 and the PrD (Fig. 4.9A).  
Point mutations in Ydj1’s individual zinc-binding domains (ZBDs) were tested for their effect on 
suppression of PrD toxicity. Mutation of ZBD1 (C143S or C201S) had no effect on Ydj1’s 
modulation of PrD toxicity (Fig. 4.9B). However, mutation of ZBDII (C162S or C185S) 
dramatically disrupted the ability of Ydj1 to suppress PrD toxicity. Thus, ZBDII of Ydj1 is 
required for yeast to tolerate overexpression of the PrD. Defects in cytoprotection by Ydj1 ZBDII 
mutants correlated with a substantial 90% decrease binding between PrD-GFP and Ydj1(C162S) 
(Fig. 4.9C). Furthermore, the pool of SDS-insoluble PrD-GFP was increased in the presence of 
Ydj1(C162S) to levels observed in the ydj1 strain (Fig. 4.9D). We found these data interesting 
because we knew that ZBDII is required for Ydj1’s protein folding function, but action of the 
ZFLR appeared dispensable for binding globular proteins (15,16,43). Thus, the data presented 
identify a critical role for the Type I Hsp40 ZFLR in binding and suppressing the toxicity of 
proteins that form amyloid-like aggregates.  
Ydj1 contains a hydrophobic depression in C-terminal Domain I (CTDI) that is required for 
folding model proteins, is conserved in Type II Hsp40s, and has been co-crystallized in a 
complex with a hydrophobic peptide (31). Since Ydj1-bound peptides in the PrD that contained 
hydrophobic peptides (Fig. 4.3), the role of CTDI in suppression of prion toxicity was 
investigated. To address whether the peptide-binding pocket of Ydj1 participates in PrD binding, 
several solvent-exposed hydrophobic residues in this groove were mutated (Fig. 4.9E). Point 
mutations in this pocket disrupt binding and refolding of luciferase in vitro (44). However, Ydj1 
peptide-binding pocket mutants were capable of suppressing PrD toxicity (Fig. 4.9F). PrD 
expression was slightly toxic in strains that harbored Ydj1(L135S). Yet, Ydj1(L135S) bound  
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Figure 4.9 Mutation in the Ydj1 ZFLR disrupts binding to the PrD. (A) Ribbon diagram of 
the x-ray crystal structure from Ydj1(110-337). Zinc binding domains in the Ydj1 ZFLR are 
noted as well as the peptide-binding pocket. (B) Cells from a ydj1 background were transformed 
with pRS315 (low copy) plasmids expressing wild type Ydj1 or the indicated ZFLR mutant from 
the YDJ1 promoter. These cells, also harboring a plasmid expressing PrD from a galactose-
inducible promoter, were serially diluted onto selective media containing galactose or glucose. 
(C) Binding between PrD-GFP and the indicated form of Ydj1 was assessed by co-
immunoprecipitation with Ydj1 antisera. Percentages below represent bound PrD-GFP levels as 
a percentage of wild type Ydj1 normalized to background (pRS315). (D) SDS-resistant PrD-GFP  
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PrD-GFP almost as well as wild type Ydj1 and no increase in SDS-insoluble PrD-GFP was 
observed in this mutant background (Fig. 4.9G & H). Thus, when peptide binding by CTDI is 
compromised through mutation, actions of the ZFLR and farnesyl moiety on Ydj1 appear 
sufficient for modulation of PrD toxicity.  
At, this point we want to note that the role of the Ydj1’s ZFLR and farnesyl moiety in binding 
to amyloid-like prion protein conformers is not limited to the PrD of Rnq1. Ydj1 binding to the 
prion form of the yeast prion Sup35 was also severely disrupted by mutation of ZBDII in the  
ZFLR and reduced by mutation of the CAAX box (Fig. 4.10). Thus, conserved domains that are 
found in Type I Hsp40s enable Ydj1 to bind proteins that assume amyloid-like states.  
Structural requirements for Ydj1 binding to HD53Q.  
 The above observations suggest the Ydj1 ZFLR participates in recognition of -rich, 
amyloid-like substrates and that it may or may not require assistance of CTDI. To determine the 
generality of the data obtained in study of the PrD, we examined structural requirements for Ydj1 
binding to a purified huntingtin fragment that contains exon 1 and a 53Q expansion (HD53Q) 
(45). While wild type Ydj1 suppressed HD53Q aggregation in a dose-dependent manner, 
Ydj1(C162S) was almost entirely defective (Fig. 4.11). Interestingly, Ydj1(I215S), which 
contains a point mutation in the peptide-binding pocket, was also inactive in suppressing HD53Q 
aggregation. I215 is located at the base of the Ydj1 polypeptide-binding pocket and may be 
required to stabilize this groove, though Ydj1(I215S) could still suppress PrD toxicity suggesting  
Figure 4.9 cont. . . . was compared between a ydj1, Ydj1, Ydj1(C162S) background by filter 
trap. (E) PyMOL model of the Ydj1 peptide-binding pocket (hydrophobic:red, basic:blue, 
acidic:yellow). Specific residues examined in this study are identified. (F) Strains from a ydj1 
background were transformed as described above with plasmids expressing wild type Ydj1 or the 
indicated polypeptide-binding mutant. These cells, also expressing galactose-inducible PrD, were 
serially diluted onto media containing galactose or glucose. (G) Binding between PrD-GFP and 
the indicated form of Ydj1 was assessed by co-immunoprecipitation with Ydj1 antisera as 
above. (H) SDS-resistant PrD-GFP was compared between a ydj1, Ydj1, and Ydj1(L135S) 
background by filter trap. For filter trap assays, panels below show protein expression levels from 
cell lysates. 
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Figure 4.10 Binding between Ydj1 and Sup35 requires the Ydj1 ZFLR and farnesylation. 
Yeast cells in a ydj1 background were transformed with plasmids expressing wild type Ydj1, 
Ydj1(C162S), or Ydj1(C406S) from the YDJ1 promoter. These cells were also transformed with a 
plasmid expressing Sup35-GFP from a CUP1 promoter. Sup35-GFP was induced as described for 
PrD-GFP. Ydj1 was co-immunoprecipitated from cell lysates generated under non-denaturing 
conditions (described in Experimental Procedures) and bound Sup35-GFP analyzed by western 
immunoblotting for GFP. Binding to Ydj1(C162S) was substantially reduced to near background 
levels. Binding to Ydj1(C406S) was also reduced, though residual binding between Ydj1(C406S) 
and Sup35-GFP was consistently observed.   
 
Figure 4.11 The Ydj1 ZLFR is required to suppress HD53Q aggregation. (A) Myc-HD53Q 
(1M) was incubated with a titration of purified Ydj1 and aggregation assessed by filter trap and 
western immunoblotting for myc as previously described (46) with the following modifications. 
First, 1M GST-myc-HD53Q was incubated in Buffer B (50 mM Tris·HCl (pH 7.0), 150 mM 
NaCl, 1 mM DTT, 1 mM phenylmethylsulfonyl fluoride,
 
50 mM KCl, 5 mM MgCl2) with 6M 
Ydj1 (wild type or the indicated mutant) and PreScission Protease to start the reaction (47). 
Reactions were incubated for 150 minutes then stopped with 4x native gel sample buffer (0.24M 
Tris-HCl pH
 
6.8, 40% glycerol, 1% Bromphenol Blue). Aggregated myc-HD53Q was analyzed 
by filter trap and western-immunoblotting with c-Myc antisera (Sigma). (B) Myc-HD53Q (1M) 
was incubated with the indicated version of Ydj1 (6M) and aggregation assessed as described 
above. 
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it is not grossly misfolded.  HD53Q includes a 17-residue peptide from exon 1 of human 
huntingtin that contains several hydrophobic motifs. Thus, we propose that Ydj1 utilizes a 
bipartite mechanism to suppress HD53Q aggregation in which b-strands in the ZFLR interact 
with the polyQ expansion and solvent-exposed residues in the hydrophobic pocket interact with 
the exon 1 peptide.  However, it was difficult to test this hypothesis because Ydj1(C162S) and 
Ydj1(I215S) were almost entirely inactive.  Never the less, function of both the ZFLR and CTDI 
are required for Ydj1 to suppress HD53Q aggregation.  
The Ydj1 ZFLR and peptide-binding pocket regulate luciferase refolding in vivo.  
 Data presented thus far suggest that Type I Hsp40s contain at least three domains that are 
required for interaction of Ydj1 with non-native substrates, yet the requirements of each are 
substrate-dependent. To test this model we compared the structural requirements for Ydj1’s 
action in suppression of PrD biogenesis to those for in vivo and in vitro folding of the globular 
protein luciferase. Luciferase was expressed from the GAL1 promoter in a ydj1 strain harboring 
Ydj1 mutants discussed above. Minimal luciferase activity was observed in the ydj1 strain, 
though very little luciferase was expressed from the GAL1 promoter (Fig. 4.12A & B). Wild type 
Ydj1 restored luciferase expression and activity. However, mutation of either ZBDI or ZBDII 
severely reduced luciferase activity even though luciferase expression levels were recovered to 
near wild type. Ydj1(C162S) still bound luciferase (data not shown) suggesting this defect 
reflects an inability of Ydj1 to maintain luciferase in a conformation that subsequently is bound 
by Hsp70 (15). Ydj1(L135S) and Ydj1(I215S) only supported luciferase activity at around ~50% 
of wild type levels. Interestingly, Ydj1(C406S) supported luciferase expression and activity to 
near wild type levels. Thus, farnesylation of Ydj1 is dispensable for in vivo folding of luciferase 
Defects exhibited by Ydj1 mutants with in vivo assays of luciferase refolding were 
recapitulated when activity of the purified forms of these proteins were monitored with in vitro 
luciferase refolding assays (Fig. 4.12C). The ability of Ydj1 to promote expression and folding of  
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Figure 4.12 Mutations in the Ydj1 ZFLR and peptide-binding pocket disrupt luciferase 
refolding in vivo. (A) Firefly luciferase was expressed in a ydj1 strain harboring the indicated 
form of Ydj1 expressed from a pRS315 plasmid under control of the YDJ1 promoter. Luciferase 
activity was measured in intact cells with a luminometer. Luciferase activity is represented as 
percent of control (wild type Ydj1). (B) Expression of firefly luciferase in yeast in the presence of 
the indicated form of Ydj1. Cell lysates were analyzed by SDS-PAGE and assessed by western 
immunobloting for luciferase and Ydj1. (C) Luciferase activity was also assessed in vitro. 
Purified firefly luciferase (50nM) was incubated with Hsp70 (0.5M) and the indicated form of 
Ydj1 (1M). Error bars represent SEM from three independent trials. (*p0.01; **p0.001).  
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Figure 4.13 Chaperone-dependent polyubiquitination requires the Ydj1 ZFLR and peptide-
binding pocket. The role of Ydj1 during in vitro polyubiquitination of a fragment from the 
CFTR ion channel (NBD-R) was assessed. Gst-NBD1-R (1M) was incubated with E1 (0.1M), 
the E2 UbcH5a (4M), the E3 ubiquitin ligase CHIP (3M), Hsc70 (2M), plus or minus the 
indicated form of Ydj1 (4M). Polyubiquitinated gst-NBD1-R was retained at the gel front while 
unmodified gst-NBD-R resolved at its predicted molecular weight. 
luciferase requires the ZFLR and CTDI, yet this process occurs when the CAAX box is not 
farnesylated.  
The Ydj1 ZFLR and peptide-binding pocket cooperate in chaperone-dependent 
polyubiquitination.  
Crystal structures demonstrate that the ZFLR and CTDI are in close proximity to each other 
(31) and these domains appear to cooperate in the process of suppressing HD53Q aggregation. To 
further study this issue we examined the contribution of the Ydj1 ZFLR and peptide-binding 
pocket in chaperone-dependent polyubiquitination reactions (31). Purified Ydj1 was incubated 
with Hsp70, the E2 UbcH5a and the E3 ubiquitin ligase CHIP to assess polyubiquitination of a 
model Gst fusion (Gst-NBD1-R, which contains nucleotide binding domain 1 and the regulatory 
domain from CFTR) (48). In the absence of Ydj1 little ubiquitination of Gst-NBD1-R was 
observed. Yet, upon addition of Ydj1, the majority of gst-NBD1-R was polyubiquitinated and 
retained at the top of the SDS-PAGE gel (Fig. 4.13A; lanes 1 and 2). This mobility shift was not 
observed in the absence of ATP, ubiquitin, E1 or any of the other components of the Hsp70/CHIP 
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E3 complex (48). The ZFLR mutants Ydj1(C201S) and Ydj1(C162S) both exhibited a reduced 
ability to support polyubiquitination of gst-NBD1-R (Fig. 4.13B; lanes 3 and 4). A similar defect 
in polyubiquitination was observed when Ydj1(I215S) was used in the reaction (Fig. 4.13B; lane 
5), but mutation of other residues in the peptide-binding pocket had no effect (Fig 4.13B lanes 8-
10).  Yet, the most dramatic reduction in Ydj1 activity was observed when ZBDII and the 
polypeptide-binding pocket were altered simultaneously (Fig. 4.13B; lanes 6 and 7). Thus, the 
Ydj1 ZFLR and peptide-binding pocket cooperate in order to modulate the conformation of non-
native proteins and this synergism is required to maintain substrates of the Hsp70/CHIP E3 ligase 
in a ubiquitination-competent state. 
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4.4 Discussion 
 Identification of distinct binding sites in the prion Rnq1 for the Type I Hsp40 Ydj1 and Type 
II Hsp40 Sis1 explains why these chaperones play different roles in prion propagation. In 
addition, these data support the concept that selective recognition of substrates by Type I and 
Type II Hsp40s serve to specify cytosolic Hsp70 functions (13,49). Sis1 binding to the non-prion 
domain serves to increase the efficiency of [RNQ
+
] assembly and mediate chaperone-dependent 
shearing of large prions into smaller seeds (4,27). However, if Sis1 is unable to bind Rnq1, then 
the ability of Ydj1 to recognize Gln/Asn-rich regions in the Rnq1 PrD enables it to regulate the 
[RNQ
+
] prion pool size.   
 Sis1 suppresses Rnq1 toxicity by increasing the efficiency of [RNQ
+
] assembly, which 
prevents the accumulation of an SDS-sensitive, toxic off-pathway species (4). Interestingly, the 
assembly of the PrD into amyloid-like, SDS-resistant particles appears more efficient than the 
assembly of Rnq1 into a similar species. The PrD is a poor substrate of Sis1, and Ydj1 action is 
required for yeast to tolerate PrD overexpression. The toxic conformer of the PrD is unknown, yet 
the cell death that occurs when Ydj1 is inactive correlates with a several-fold increase in the 
accumulation of SDS-resistant forms of PrD. Thus, the toxic species of Rnq1 and its PrD appear 
different and the cell’s ability to suppress their accumulation is dependent upon distinct Hsp40s. 
These data help explain why Type I and Type II Hsp40s have differential effects in suppressing 
conformational disease (50). 
 Our studies identify the ZFLR, CTDI, and farnesyl moiety as domains in Type I Hsp40s that 
are required for modulating the conformation of non-native proteins. Interestingly, the 
requirement of these domains in Ydj1 action is substrate specific. Mutation of the ZFLR and 
farnesyl moiety, but not CTDI, interfered with Ydj1’s ability to bind the amyloid-like form of the 
PrD and Sup35. In contrast, Ydj1 required action of both the CTDI and the ZFLR, but not the 
farnesyl moiety to fold luciferase. Furthermore, apparent synergy between the ZFLR and CTDI 
enabled Ydj1 to facilitate polyubiquitination of misfolded proteins by the quality control E3 
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ubiquitin ligase CHIP. Thus, Ydj1 contains at least three regions that facilitate substrate binding 
and different combinations are utilized to recognize different protein conformers. Through the use 
of multiple domains to mediate interaction with non-native substrates, Ydj1 can cooperate with 
Hsp70 to facilitate the biogenesis or degradation of a broad range of substrates. Mutation of 
hydrophobic residues in the peptide-binding site from Type I or Type II Hsp40s causes defects in 
cell viability and chaperone function (44,51). However, the Ydj1 peptide-binding pocket is not 
sufficient to perform all it’s chaperone duties and depending on the nature of the substrate, it can 
be dispensable, or its action is assisted by the ZFLR and/or the C-terminal farnesyl moiety. 
Structural data show that the tip of the ZFLR (adjacent to ZBDII) contains a pair of anti-parallel 
ß-strands whose orientation and folding appears to be stabilized by ZBDII (31). Interestingly, the 
Ydj1 CTDI is also constructed from anti-parallel ß-strands and the co-crystal structure of a 
Ydj1:peptide complex suggests that substrate binding involves formation of an additional -
strand with the two-stranded, anti-parallel ß-sheet in the peptide-binding pocket. There are a 
number of Gln and Asn side-chains exposed on the surface of the anti-parallel ß-strands at the tip 
of the ZFLR. Thus, it is conceivable that the ß-strands at the tip of the ZFLR form a ß-strand with 
exposed surfaces of amyloid-like proteins or regions of protein folding intermediates. 
Simultaneous binding of substrates to the ZFLR and CTDI may then hold the substrate in a 
conformation that can be recognized by Hsp70. 
 Models for Type I Hsp40 structure built from small x-ray scattering data and x-ray crystal 
structures of Ydj1 fragments demonstrate that Type I Hsp40s function as homodimers (14). The 
ZFLRs in Ydj1 homodimers are located in a central domain that controls the shape and functional 
specificity of Ydj1 (13,14). The requirement for the Type I Hsp40 ZFLR in substrate binding 
further explains the functional differences observed between Type I and Type II Hsp40s (13). 
Defects in Ydj1 function caused by mutation of the ZFLR could be due to alteration of Ydj1’s 
quaternary structure. However, monomeric forms of Ydj1 retain the ability to suppress to PrD 
toxicity, so this is unlikely. Thus, the ZFLR appears to control the quaternary structure of  Type I 
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Hsp40s and can also directly participates in substrate binding. Additional, structural studies are 
now required to define the mechanism for ZFLR action in these processes 
 It has been thought for some time that lipid modification of the C-terminal CAAX box of 
Type I Hsp40s only serves to localize these chaperones to intracellular membranes that include 
the ER (21,22). However, large pools of Ydj1 are cytosolic and it is now clear that farnesylation 
of Ydj1 enhances its ability to bind cytosolic substrates such the prion Rnq1.  In addition, 
farnesylation of Ydj1 was recently demonstrated to be required for proper folding of kinase Ste11 
(52). Interestingly, farnesyl dependent binding of Ydj1 to Ste11 occurs independent of the ZFLR 
and peptide-binding pocket (52). These data are consistent the model we put forth which suggests 
that Type I Hsp40s contain multiple domains that are capable of participating in the binding of 
non-native polypeptides.  
 The action of a lipid moiety in polypeptide binding by Ydj1 is a novel and somewhat 
surprising finding. Importantly, a number of human Hsp40s are farnesylated or 
geranylgeranlyated, so this mechanism for substrate binding appears to be conserved (12). The 
simplest mechanism for farnesyl action in Hsp40 chaperone function is interaction between the 
farnesyl chain and hydrophobic surfaces of protein folding intermediates. However, the farnesyl 
moiety of Ydj1 could also influence the conformation of Ydj1 and thereby regulate it’s substrate 
specificity (53). 
 A point that should be emphasized is that farnesylation of Ydj1 is critical for biogenesis of 
some, but not all Ydj1 functions. Farnesylation of Ydj1 is not required for normal growth of 
yeast, but is required for cells to survive heat-stress (22). Ydj1 cooperates with Hsp70 and 
Hsp104 to break up large aggregates (54). In the context of PrD toxicity, it is possible that 
farnesylation enables Ydj1 to bind large PrD assemblies and assist Hsp104 in disaggregation. 
This activity would help control the PrD pool size and perhaps suppress PrD toxicity. However, 
while efficient binding between Ydj1 and the PrD required farnesylation, the residual Ydj1 
interaction appeared sufficient to control the pool size of SDS-resistant PrD aggregates. In this 
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situation, the cellular threshold to tolerate SDS-resistant PrD accumulation may be reduced 
because Ydj1(C406S) is unable to properly fold other cellular proteins required for stress 
protection. For example, Ydj1 is required for the maturation of numerous kinases implicated in 
stress response (55) and farnesylation of Ydj1 is required for proper folding of at least one kinase 
(52). Thus, it is conceivable that reduced stress kinase activity could sensitize yeast that harbor 
the non-farnesylated form of Ydj1 to PrD toxicity when the pool size of SDS-resistant PrD is not 
dramatically elevated.  
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4.5 Materials and Methods 
Yeast strains and plasmids- All experiments were conducted in the yeast strain BY4741 (MATa 
his3, leu2, met15, ura3) in a wild type, ydj1 (ydj1::KAN1), or ram1 (ram1:KAN1) 
background. Yeast strains were cured of prion seeds by three sequential passages on YPD media 
containing 3mM Guanidine-HCl. Ydj1 wild type and mutant constructs were expressed from the 
endogenous YDJ1 promoter in a pRS315 plasmid backbone (15). The YDJ1 open reading frame 
was also subcloned into a pRS315 backbone behind a glyceraldehyde phosphate dehydrogenase 
(GPD) promoter. The prion domain of Rnq1 (PrD:aa153-405) was generated by PCR 
amplification of nucleotides 459-1215 from RNQ1 and subcloned in a pRS416 backbone behind 
the GAL1 promoter or into a pRS316 backbone behind the CUP1 promoter with an EGFP tag at 
the C-terminus. Sup35 was amplified from genomic DNA and inserted downstream of the CUP1 
promoter and upstream of an EGFP tag in a pRS416 background. Point mutants were generated 
using a Stratagene Quikchange mutagenesis kit. Yeast strains were generated by transformation 
using the lithium acetate method and selected on synthetic minimal media supplemented with 
amino acids required for survival. 
Cell Viability Assay- Freshly transformed cells harboring pRS416-RNQ1 or PrD with the 
indicated version of YDJ1 were serially diluted on minimal selection media containing 2% 
galactose or 2% glucose. Plates were incubated at 30C for 3-4 days and photographed. 
Fluorescence microscopy- Cells transformed with Rnq1-GFP or PrD-GFP under the control of 
the CUP1 promoter were induced with 50M CuSO4 for two hours then mounted on a glass slide 
and visualized with a Nikon Eclipse E600 fluorescence microscope. 
Differential Centrifugation- Yeast cells were grown to mid-log phase and Rnq1-GFP or PrD-
GFP induced for 4 hours with 50M CuSO4. Cells were lysed in Buffer A (50mM Hepes pH 7.4, 
150mM NaCl, 0.1% Triton X-100, 1mM PMSF, 1X Protease inhibitor cocktail[Roche]) with 
glass beads in 30 second intervals for 8 cycles. Crude lysates were cleared of cell debris at 
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3000rpm for 3 min. About 100µg protein extract was subjected to high-speed centrifugation 
(100,00 x g) in a Beckman Type 70Ti rotor for 30 minutes. Supernatant and pellet fractions were 
resolved with input (10%) by SDS-PAGE and assessed by western immunoblotting. 
Gel Filtration- Yeast cells were grown and lysed in Buffer A as described above. About 5mg 
protein extract was applied to a Sephacryl S-500HR gel filtration column (GE Healthcare). The 
column was calibrated with molecular weight markers from Amersham. Every other fraction was 
loaded on an acrylamide gel and analyzed by SDS-PAGE.  
Rnq1 Peptide Array- A Rnq1 25-mer peptide array from Jenri Peptide Technologies was 
screened with purified Ydj1 according to manufacturer’s instructions and as previously described 
(4). 
Co-immunoprecipitation- Rnq1-YFP, PrD-YFP, and NPrD-YFP were expressed in [RNQ
+
] 
cells from a galactose-inducible promoter and cell lysates were generated in buffer A and co-
immunoprecipitations performed with Ydj1 antisera as described in main text. To determine 
binding with Sis1, Rnq1-GFP and PrD-GFP were expressed from a CUP1 promoter in [RNQ
+
] 
cells and cell lysates generated in buffer A. 1uL polyclonal Sis1 antisera was used to co-
immunoprecipitate Sis1 and non-specific pre-immune antisera was used as a negative control to 
detect background binding. Rnq1-GFP or PrD-GFP were induced in wild type or ydj1 cells 
expressing the indicated form of Ydj1 as described above. Cell lysates were prepared in Buffer A 
as described above. Ydj1 was co-immunoprecipitated from about 100µg protein extract using 
Ydj1 polyclonal antisera and protein G-agarose beads (Roche) with standard techniques. Bound 
protein was analyzed by SDS-PAGE with 10% original lysate representing input.  
Filter Trap Assay- PrD-GFP was induced and cells were lysed in Buffer A as described above. 
Approximately 20µg protein extract was added to sample buffer (2% SDS, 62.5mM Tris-HCl 
pH6.8, 1mM EDTA, 5% glycerol, 2% -mercaptoethanol) then loaded onto a cellulose acetate 
membrane assembled in a slot blot apparatus. The membrane was washed in 0.1% SDS and 
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retained PrD-GFP assessed by immunobloting for GFP (Roche). Lysates were also analyzed by 
SDS-PAGE to determine protein expression levels. Western immunoblotting for 3-
phosphoglycerate kinase (PGK) (Molecular Probes) was used as a load control.  
Luciferase Reporter Assay- Yeast cells harboring firefly luciferase on a galactose-inducible 
promoter and the indicated version of YDJ1 were grown to mid-log phase with 2% raffinose and 
luciferase induced with 2% galactose. Luciferase activity was measured as previously described 
(56) with a TD 20/20 luminometer. For in vitro luciferase refolding assays, firefly luciferase was 
purified and refolding measured as previously described (15). A two-sampled t-test (assuming 
unequal variances) was used to generate p-values comparing luciferase activity between wild type 
and mutant Ydj1. 
Reconstitution of Chaperone-Dependent Polyubiquitination- Recombinant chaperones were 
purified and experimental conditions were conducted as previously described (48) substituting 
recombinant Ydj1 or the mutant as the Hsp40. 
Immunofluorescence - Thioflavin T staining was performed as previously described (4) by 
expressing PrD-RFP in yeast overnight from a CUP1 promoter.  
Analysis of SDS-resistant aggregates - SDS-resistant aggregates were assessed by semi-
denaturing gel electrophoresis (SDD-AGE) performed as previously described (4). SDS-resistant 
aggregates were also assessed by filter trap performed as described above 
Huntingtin Aggregation Assay - Aggregation of GST-myc-HD53Q was performed as 
previously described (46) with the following modifications. First, 1M GST-myc-HD53Q- was 
incubated in Buffer B (50 mM Tris·HCl
 
(pH 7.0), 150 mM NaCl, 1 mM DTT, 1 mM 
phenylmethylsulfonyl fluoride,
 
50 mM KCl, 5 mM MgCl2) with 6M Ydj1 (wild type or the 
indicated mutant) and PreScission Protease to start the reaction (47). Reactions were incubated 
for 150 minutes then stopped with 4x native gel sample buffer (0.24M Tris-HCl pH
 
6.8, 40% 
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glycerol, 1% Bromphenol Blue). Aggregated myc-HD53Q was analyzed by filter trap and 
western-immunoblotting with c-Myc antisera (Sigma). 
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Chapter Five 
A microtubule-dependent quality control pathway protects misfolded, cytosolic proteins from 
aggregation 
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5.1 Abstract 
 
Protein misfolding is a constant cellular burden as unfolded polypeptides must be held in soluble state 
for refolding or degradation by protein quality control factors. Failure to efficiently process misfolded 
proteins can result in aggregation which threatens protein homeostasis. Molecular chaperones and E3 
ubiquitin ligases cooperate to triage misfolded proteins for refolding or degradation. We find that 
perturbation of specific steps in the degradation of a multi-domain, misfolded protein in the cytosol 
has distinct outcomes on the propensity of this protein to aggregate in the cell. Removing the E3 
ubiquitin ligases Ubr1 or San1 causes soluble forms of this misfolded protein to accumulate at a 
perinuclear compartment. Conversely, interfering with the Type I Hsp40 Ydj1 or perturbing the 
microtubule cytoskeleton selectively partitioned this misfolded protein in insoluble aggregates and 
impaired degradation. Polyubiquitination of this misfolded protein was unaffected suggesting that 
polyubiquitinated proteins are particularly sensitive to protein aggregation. Elevating levels of the 
Type II Hsp40 Sis1 rescued protein degradation during microtubule dysfunction. As a result, 
disrupting specific stages in degradation of a misfolded protein shifts the folding equilibrium toward 
aggregation however back-up pathways protect cells from the accumulation of protein aggregates.  
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5.2 Introduction 
Cells are continuously challenged by the formation of misfolded protein species. Unfolded 
polypeptides expose hydrophobic amino acids that are normally buried in the core of the native 
protein. As a consequence, unfolded polypeptides have a strong propensity to aggregate in the cell 
(1). Protein misfolding and aggregation induce global deficiencies in protein homeostasis and 
underlie a variety of human diseases especially pathologies associated with aging (2-4). Sophisticated 
protein quality control (PQC) pathways function at each stage of a protein’s life cycle to prevent 
aberrant protein aggregation and partition non-native polypeptides for refolding or degradation (5). 
Misfolded proteins that are beyond repair are targeted for degradation by the ubiquitin-proteasome 
system (UPS) (6). The cooperative action of molecular chaperones and E3 ubiquitin ligases recognize 
non-native protein conformers and recruit E2 ligases to polyubiquitinate the misfolded protein (7). 
Ubiquitin receptors bind polyubiquitin chains and physically tether polyubiquitinated proteins to the 
proteasome to facilitate degradation (8). At each step in this pathway, misfolded proteins must be held 
in a soluble state competent for degradation by the proteasome. How protein quality control factors 
function in a concerted action to deliver misfolded proteins to the proteasome is a major unanswered 
question in the field.  
The Hsc/Hsp70 molecular chaperone family (herein generally referred as Hsp70s) plays a 
major role in recognizing non-native polypeptides and suppressing protein aggregation (5,9). Hsp70 
polypeptide binding is regulated by cycles of ATP binding and hydrolysis (10). ATP hydrolysis is 
rate-limiting, but a family of Hsp70 co-chaperones known collectively as Hsp40s (or J-proteins) 
stimulate Hsp70 ATPase activity via a conserved J-domain (11-14). ATP hydrolysis by the Hsp70 
causes a conformational change that increases Hsp70 substrate affinity. Hsp40 molecular chaperones 
have evolved specialized protein domains that tether Hsp70 function to a wide variety of basic 
cellular activities including protein degradation (15,16). For example, the yeast Hsp40 Ydj1 possesses 
multiple substrate binding domains that recognize diverse non-native proteins and suppress protein 
aggregation (17-19). This activity is crucial for holding non-native polypeptides in a refolding 
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competent state (20,21) or a conformation favorable for polyubiquitination by E3 and E2 ubiquitin 
ligases (22-24). Sis1 is another Hsp40 in the yeast cytosol that can bind non-native polypeptides.  
While Ydj1 and Sis1 share some overlapping activities (25), these Hsp40s also couple Hsp70 to very 
distinct functions in the cell (21,26). The conventional model is that Hsp70/Hsp40s bind non-native 
polypeptides and recruit additional PQC factors including E3 ubiquitin ligases to triage non-native 
polypeptides for refolding or degradation.  
In addition to the Hsp70/Hsp40 chaperone machine, E3 ubiquitin ligases supply another layer 
of selectivity in PQC. For example, the mammalian E3 ligase CHIP (carboxyl terminus of the Hsc70-
interacting protein) promotes degradation of misfolded proteins in the cytosol and ER membrane 
(22,27-29). However, CHIP also possesses co-chaperone activity and contributes to Hsc70-dependent 
refolding of non-native polypeptides (30-32). As a result, specialized chaperone/E3 ligase complexes 
can selectively partition misfolded proteins between refolding and degradation pathways. Budding 
yeast lack a CHIP ortholog, yet the E3 ubiquitin ligases Ubr1, San1, and Doa10 have been shown to 
mediate degradation of misfolded cytosolic  proteins (23,33-37). Ubr1 has been studied 
predominantly for its role in N-End-rule degradation (38,39). However, Ubr1 can also suppress 
protein aggregation (23) and deletion of UBR1 sensitizes yeast to a variety of stress-inducing agents 
suggesting this E3 ligase has broad influence in protein homeostasis (23,35). San1 is predominantly 
nuclear and participates in degradation of misfolded proteins in the nucleus (40). Nonetheless, San1 is 
required for efficient degradation of misfolded, cytosolic proteins in conjunction with Ubr1 or with 
the ER membrane E3 ligase Doa10 (34-36). How misfolded proteins are selectively targeted by these 
distinct E3 ligase pathways for protein degradation is currently unknown.  
Under conditions of proteasome dysfunction, misfolded proteins are selectively targeted via 
the microtubule cytoskeleton to specialized protein quality control compartments in the cell (41). For 
example, Kaganovich et al demonstrated that polyubiquitinated proteins are held in a soluble state at 
a perinuclear site called the JUNQ compartment. Alternatively, insoluble, or amyloidogenic proteins 
are trafficked to a perivaculouar compartment called the IPOD (42,43). Thus, if misfolded proteins 
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escape the PQC pathways described above, then back-up pathways redirect these proteins to specific 
intracellular locations (44). Whether compartments such as the JUNQ and IPOD function in basal 
PQC is still unclear. Polyubiquitination is an important targeting signal for selectively trafficking 
misfolded proteins to the JUNQ. As such, molecular chaperones and E3 ligases function at a critical 
intersection by which misfolded proteins are targeted to the proteasome for degradation or diverted to 
quality control compartments via the microtubule cytoskeleton. As a misfolded protein is funneled 
through multiple quality control factors, it is still unclear how PQC complexes suppress aberrant 
aggregation at each step en route to the proteasome and how interfering with distinct components 
influences the fate of a misfolded protein. 
In this study, we demonstrate that perturbation of individual steps in the degradation of a 
misfolded, cytosolic protein differentially affects aggregation of this protein. For example, loss of the 
E3 ubiquitin ligases Ubr1 or San drives soluble forms of this misfolded protein to accumulate in a 
juxta-nuclear compartment. In contrast, loss of the Type I Hsp40 Ydj1 partitions this misfolded 
protein into an insoluble state and abrogates degradation. Surprisingly, disrupting the microtubule 
cytoskeleton similarly drove this misfolded protein to form insoluble aggregates and resulted in a lag 
in degradation. Interfering with Ydj1 or the microtubule cytoskeleton did not affect ubiquitination of 
this misfolded protein suggesting that PQC factors are required for holding polyubiquitinated proteins 
in a soluble state before delivery to the proteasome. Interestingly, microtubule depolymerization also 
induced aggregation of von Hippel Lindau protein however degradation of this misfolded protein was 
accelerated. Thus, misfolded proteins are differentially susceptible to perturbations in cellular PQC 
factors and back-up pathways are present to remove aggregated proteins.  
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5.3 Results  
Ydj1 holds a misfolded, cytosolic protein in a soluble state. 
To analyze how protein quality control factors protect misfolded proteins from aggregation 
we examined the degradation pathway of a labile, multi-domain protein. This protein (herein referred 
to as slGFP for short-lived GFP) consists of two GFP moieties that are flanked at the N-terminus by a 
126 amino acid domain enriched in hydrophobic residues (Figure 5.1A) (45). Importantly, slGFP is 
modular and contains natively folded domains as well as an unstructured region with several putative 
chaperone-binding sites (Figure 5.2)(26,46). Cycloheximide-chase analysis demonstrated that slGFP 
was unstable with approximately a 15 minute half-life (Figure 5.1B). Treatment with the proteasome 
inhibitor MG-132 blocked turnover of this protein indicating that slGFP is degraded via the ubiquitin-
proteasome system. Thus, slGFP is a model misfolded protein that is targeted for degradation and 
perturbing individual steps in the pathway will reveal how specific PQC factors protect slGFP from 
aggregation.  
Several sequences in the N-terminus of slGFP matched putative binding sites for the Type I 
Hsp40 Ydj1 (47). Ydj1 participates in degradation of numerous misfolded proteins in the cytosol and 
ER membrane (24,34,35,37,48,49), thus we predicted that Ydj1 would be involved in the degradation 
of slGFP. Indeed, slGFP degradation was delayed in a ∆ydj1 strain to a half-life of over 60min 
(Figure 5.1C). A delay in turnover was also observed in the presence of a temperature sensitive allele 
of YDJ1 (Figure 5.2B) suggesting that Ydj1 is required for slGFP degradation.  
Ydj1 functions as a chaperone to hold non-native polypeptides in a soluble state and prevents 
aggregation (19,20). Accordingly, we investigated whether deleting YDJ1 impacted slGFP solubility. 
High-speed centrifugation analysis of yeast cell extracts demonstrated that slGFP was shifted to a 
triton-insoluble state in a ∆ydj1 strain (Figure 5.1D). Ydj1 has been shown to cooperate with Hsp70 
and E3 ubiquitin ligases to promote polyubiquitination of multiple non-native polypeptides 
(18,24,35,48).   
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Figure 5.1 Ydj1 holds a misfolded, cytosolic protein in a soluble state. A) Domain structure of 
short-lived reporter protein (slGFP) with N-terminal domain and two GFP moieties. B)  
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Figure 5.2 Ydj1-151 delays slGFP degradation. A) Amino acid sequence of N-terminal domain 
from slGFP B) Turnover of slGFP in wildtype or ydj1-151 strain at 37°C. Quantification of GFP 
signal is shown on the right. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1 . . .  cont Cycloheximide-chase (CHX) analysis of slGFP turnover in ∆pdr5 cells treated 
with DMSO or the proteasome inhibitor MG-132 (100μM). C) Turnover of slGFP in wildtype (WT) 
or a ∆ydj1 strain was assessed by cycloheximide chase analysis. Quantification of three independent 
experiments is shown below in which GFP signal is represented as a percentage of signal at start of 
chase (0min). D) Differential, high speed centrifugation to examine solubility of slGFP reporter in 
WT or a ∆ydj1 strain (T-total, S-supernatant, P-pellet). D) Ubiquitination of slGFP in WT or a ∆ydj1 
strain. SlGFP was immunoprecipitated from WT or ∆ydj1 lysates (αYFP IP). Quantification of three 
independent experiments is shown on the right as a ratio of ubiquitin signal to level of 
immunoprecipitated GFP and normalized to WT. Error bars represent ±1SEM.Total input levels are 
shown on the left (Whole cell lysates). 
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We expected that slGFP ubiquitination would be reduced in a ∆ydj1 background. To test this 
hypothesis, slGFP was immunoprecipitated from wildtype or ∆ydj1 lysates and analyzed by western 
blotting for ubiquitin. However, there was a slight increase in the pool of ubiquitinated slGFP in a 
∆ydj1 strain background compared to wildtype (Figure 5.1E). Thus, Ydj1functions to hold 
polyubiquitinated forms of slGFP in a soluble state and without this Hsp40, polyubiquitinated forms 
of slGFP are unable to be degraded by the proteasome.  
The slGFP reporter is degraded by the Ubr1/San1 E3 ligases  
If polyubiquitinated forms of slGFP aggregate when this misfolded protein cannot reach the 
proteasome, we were interested if interfering with ubiquitination of slGFP would have a similar 
effect. Several E3 ubiquitin ligases including Ubr1, San1, and Doa10 are implicated in degradation of 
misfolded, cytosolic proteins (23,33-37). SlGFP was stabilized in ∆ubr1 and ∆san1 strain 
backgrounds yet not in a ∆doa10 strain background (Figure 5.3A). Consistent with these 
observations, slGFP ubiquitination was decreased in a ∆ubr1 or a ∆san1 background (Figure 5.4A). 
Thus, slGFP is degraded in a Ubr1/San1-dependent manner.  
Steady state levels of slGFP accumulate in the absence of ∆ubr1 or a ∆san1 (Figure 5.3 and 
Figure 5.4B). As a consequence, we expected that excess levels would drive slGFP to aggregate in an 
insoluble state. However, slGFP remained predominantly soluble in either a ∆ubr1 or ∆san1 strain 
background (Figure 5.3C). To determine if slGFP accumulated in a specific intracellular location or 
was globally diffuse, the localization of slGFP in these strains was investigated under fluorescence 
microscopy. In a wildtype background, slGFP is diffuse throughout the cytosol in a majority of 
cells(>90%). In ∆ubr1 or ∆san1 strains, the percentage of cells displaying a single slGFP aggregate 
significantly increased (Figure 5.3). Interestingly, these aggregates were often localized proximal to 
the nucleus and did not colocalize with Rnq1-mRFP (Figure 5.4) or the spindle-pole body marker 
Spc72 (data not shown) suggesting these aggregates do not represent IPODs or aggresomes. If 
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Figure 5.3 Ubr1 and San1 E3 ligases participate in degradation of slGFP reporter. A) Turnover 
of slGFP reporter in WT, ∆ubr1, ∆san1 or ∆doa10 strain was assessed by cycloheximide chase 
analysis. Quantification of three independent experiments is shown on the right. B) Steady state levels 
of slGFP from WT, ∆ubr1, or ∆san1 strains. C) Detergent solubility of slGFP in WT, ∆ubr1, or 
∆san1 strains was assessed after high speed centrifugation (T-total, S-supernatant, P-pellet). D) 
Localization of slGFP reporter was analyzed in WT, ∆ubr1, ∆san1 or ∆doa10 strains by fluorescence 
microscopy. Quantification of slGFP aggregates in different strain backgrounds is shown on the right 
(*p<0.05 n=500 cells in three independent experiments). Error bars represent ±1 SEM. E) 
Colocalization of slGFP aggregates in WT, ∆ubr1, or ∆san1 strains with Rnq1-mRFP under 
fluorescence micrscopy (DAPI is overlaid in blue). F) Localization of slGFP in WT, ∆ubr1, or ∆san1 
strains treated with DMSO or benomyl for 30 minutes.  
103  
 
 
Figure 5.4 Ubiquitination and accumulation of slGFP in ∆ubr1 and ∆san1 backgrounds. A) 
Ubiquitination of the slGFP reporter in WT, ∆ubr1, or ∆san1 strains expressing myc-ubiquitin. 
SlGFP was immunoprecipitated from cell extracts with anti-YFP antisera and immunoprecipitated 
material assessed by western immunobloting for myc and GFP. B) Localization of slGFP under 
fluorescence microscopy. Upper panel shows WT cell expressing slGFP under same exposure as 
∆ubr1 strain shown on bottom. Middle panel shows WT cell under longer exposure to normalize 
intensity of signal to ∆ubr1 strain. Merge images show DIC, DAPI, and GFP signal together. 
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these perinuclear aggregates represent intracellular PQC compartments, the formation of this structure  
should be dependent upon the microtubule cytoskeleton. To test this prediction, cells were treated 
with the microtubule depolymerizing drug benomyl. In ∆ubr1 or ∆san1 cells treated with benomyl, 
slGFP was not longer localized in juxtanuclear foci yet formed multiple aggregates that were 
dispersed throughout the cytosol (Figure 5.3F). Interestingly, benomyl also induced slGFP 
aggregation in a wildtype strain suggesting that an intact microtubule cytoskeleton is normally 
required for suppressing aggregation of a misfolded protein.  
Microtubules are required for holding slGFP in a soluble state  
While microtubules are required for trafficking misfolded proteins to specialized 
compartments under stress (ex. proteasome inhibition)(44), a basal role for microtubules in PQC has 
not been investigated. Timecourse analysis revealed that small slGFP aggregates were visible after 
only 15 minutes post-benomyl treatment and several large, cytosolic aggregates were observed by 45 
minutes (Figure 5.5A). The kinetics of slGFP aggregation are consistent with previous reports 
demonstrating that benomyl induces microtubule depolymerization as early as 15 minutes (50). Upon 
microtubule depolymerization, slGFP relocalized in two distinct pools, small aggregates dispersed 
throughout the cytosol and a large, single aggregate that co-localized with Rnq1-mRFP foci (Figure 
5.5B-arrow) suggesting pools of the slGFP reporter might become insoluble. High speed 
centrifugation analysis demonstrated that a substantial fraction of the slGFP reporter redistributed 
from a triton-soluble to a triton-insoluble state after microtubule depolymerization (Figure 5.5C). 
Benomyl-induced slGFP aggregation was independent of the [RNQ+] prion (Figure 5.6A&B) 
suggesting co-colocalization with Rnq1 was coincidental with slGFP becoming insoluble after 
benomyl treatment and not a result of slGFP being templated by an amyloidogenic prion. Importantly, 
benomyl did not result in aggregation of monomeric GFP (Figure 5.5D) and did not induce a heat 
shock response suggesting that microtubule dysfunction does not cause general misfolding of cellular 
proteins (Figure 5.5E). Thus, perturbing the microtubule cytoskeleton interferes with quality control 
of a misfolded, cytosolic protein. 
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Figure 5.5. Benomyl treatment causes slGFP to form insoluble aggregates. A) Fluorescence 
microscopy of slGFP in cells treated with MG-132 after the indicated time (upper panel). 
Colocalization of slGFP and Rnq1mRFP in cells treated with DMSO or MG-132 (lower panel).  
Merge images show slGFP and Rnq1-mRFP with DAPI overlay (blue). B) Localization of the slGFP 
reporter in cells treated with treated with MG-132 alone or in combination with benomyl for 30 
minutes. C) Timecourse of slGFP aggregation after benomyl treatment (DAPI is overlaid in blue). F) 
Colocalization of slGFP aggregates with Rnq1-mRFP after benomyl treatment. Arrow indicates 
slGFP aggregate that colocalizes with Rnq1-mRFP inclusion H) Detergent-solubility of slGFP 
reporter after high speed centrifugation from cells treated with DMSO or benomyl (T-total, S-
supernant, P-pellet) G) Localization of GFP in cells treated with DMSO or benomyl. 
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Figure 5.6 Benomyl-induced slGFP aggregation is [RNQ+] independent. A) SlGFP localization in 
[rnq-] cells treated with DMSO or 40μM benomyl for 30 minutes (left panel). DAPI is shown with 
blue overlay. Rnq1-YFP expressed from the GAL1 promoter for 1 hour in [rnq-] cells treated as 
described for slGFP. B) Turnover of Rnq1-YFP in [rnq-] cells pretreated with DMSO or benomyl 
demonstrating that Rnq1YFP is stable in this background.  
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Disrupting microtubule dynamics selectively impacts degradation of misfolded proteins  
If depolymerizing the microtubule cytoskeleton induces slGFP aggregation, what is the 
consequence on degradation of this misfolded protein? Cells expressing slGFP were treated with 
benomyl for 10 minutes and slGFP degradation analyzed by cycloheximide-chase analysis. Benomyl 
treatment extended the slGFP half-life from 15 minutes to approximately 50 minutes (Fig 5.7A). To 
alter microtubule dynamics by an alternative method, we expressed a dominant-lethal form of the α-
tubulin subunit Tub1(E255A)  in yeast. This mutant incorporates into polymerizing microtubules and 
results in static microtubules (51). Like benomyl, expression of Tub1(E255A) also caused a lag in 
slGFP degradation suggesting that a dynamic microtubule cytoskeleton is required for the efficient 
degradation of a misfolded protein (Figure 5.7B).  
We were interested in whether the microtubule cytoskeleton broadly influences solubility and 
degradation of short-lived proteins or do specific misfolded proteins rely on this pathway. To test this 
question, the turnover and localization of several unstable proteins was assessed after benomyl 
treatment. Recently, Heck et al showed that a truncated form of the glycolytic enzyme Gnd1(tGnd1) 
is a short-lived substrate for the E3 ubiquitin ligases San1 and Ubr1 (35). Disrupting the microtubule 
cytoskeleton induced aggregation of 3HA-tGnd1GFP with similar kinetics to slGFP (Figure 5.8A). 
Moreover, benomyl treatment extended the half-life of 3HA-tGnd1GFP from 15 min to 25 min (Fig. 
5.8B). Therefore, interfering with the microtubule cytoskeleton disrupts quality control of multiple 
misfolded proteins in the cell.  
The misfolded proteins examined thus far are rapidly degraded (half-life<30min) suggesting 
that PQC machinery bypasses repair and targets slGFP and tGnd directly for degradation. Other 
misfolded proteins can exist in a conformation that is accessible to both folding and degradation 
factors. For example, folding of von Hippel Lindau (VHL) protein requires chaperone-dependent 
assembly with partner proteins to form a stable ternary complex (52-54). In the absence of these 
partner proteins, VHL folding is inefficient and VHL is targeted for degradation by a distinct network 
of PQC factors. As a result, VHL is different from from the other misfolded proteins analyzed in that  
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Figure 5.7. Disrupting microtubule dynamics inhibits slGFP degradation.  A) Cycloheximide-
chase analysis of slGFP turnover in cells pretreated with DMSO or benomyl for 10 minutes. 
Quantification of three independent experiments is shown on the right. B) Cycloheximide-chase 
analysis of slGFP after expression of tub1(E355A) for 2 hours. Quantification of three independent 
experiments is shown on the right. 
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Figure 5.8 Benomyl selective impacts solubility and degradation of misfolded proteins. A) 
Timecourse of 3HA-tGnd1GFP aggregation after benomyl treatment under fluorescence microscopy 
(DAPI overlay in blue). B) Cycloheximide-chase analysis of 3HA-tGnd1GFP in cells pretreated with 
DMSO or benomyl as described above. Quantification of three independent experiments is shown on 
the right. Error bars on quantification represent ±1SEM. C) Timecourse of GFP-VHL aggregation 
after benomyl treatment under fluorescence microscopy (DAPI overlay in blue). D) Cycloheximide-
chase analysis of GFP-VHL after treatment with DMSO or benomyl. Quantification of three 
independent experiments is shown below. E) Solubility of GFP-VHL after high speed centrifugation 
in cells treated with DMSO or benomyl. F) GFP-VHL aggregates do not colocalize with Rnq1-mRFP 
foci after benomyl treatment. G) Cells expressing GFP-VHL were treated with benomyl for 30 
minutes then treated with cycloheximide and cells visualized at the indicated times. On the right, cells 
expressing slGFP were treated as described for GFP.  
110  
 
 
 
Figure 5.9 Expression of dominant-lethal Tub1 does not affect GFP-VHL turnover. A) Cells 
transformed with an empty vector or pGAL-Tub1(E255A) were treated with 2% galactose for 2 
hoursto induce GFP-VHL and dominant-lethal Tub1. Turnover of GFP-VHL was assessed by 
cycloheximide chase analysis. Quantification of three independent experiments is shown below. Error 
bars represent ±1 SEM.  
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the half-life of VHL is longer than slGFP and tGnd1 and degradation of VHL is independent of YDJ1 
(55). Depolymerizing microtubules rapidly induced aggregation of GFP-VHL (Figure 5.8C). 
However, in striking contrast to slGFP or tGnd1, benomyl treatment accelerated degradation of GFP-
VHL from a half-life of approximately 60 minutes to 30 minutes (Figure 5.8D). Similar results were 
observed when GFP-VHL was co-expressed with tub1(E255A) (Figure 5.9). Consequently, 
interfering with the microtubule cytoskeleton induces aggregation of a wide-variety of misfolded 
proteins yet selectively impairs degradation of a subset of unstable proteins. 
We were surprised that benomyl induced GFP-VHL aggregation yet concurrently accelerated 
degradation because protein aggregates are considered poor substrates for the proteasome (56). One 
possibility is that under conditions of microtubule dysfunction, GFP-VHL self-assembled into 
aggregates that are biochemically distinct from the aggregates formed by slGFP. Indeed, GFP-VHL 
remained predominantly triton-soluble after benomyl treatment (Figure 5.8E) and GFP-VHL 
aggregates did not co-localize with Rnq1-mRFP foci (Figure 5.8F). To be degraded, GFP-VHL 
aggregates would need to be dissolved to release unfolded, monomeric GFP-VHL so it can be 
degraded by the proteasome. To test this hypothesis, the fate of benomyl-induced GFP-VHL 
aggregates was monitored after cycloheximide treatment. After only 7.5min post-cycloheximide 
treatment GFP-VHL aggregates were smaller and less prominent (Figure 5.8G). By 15 minutes, 
which is less than one GFP-VHL half-life, GFP-VHL was predominantly diffuse in most cells. In 
contrast, microtubule depolymerization generated slGFP aggregates that persisted beyond 15 minutes 
after cycloheximide treatment (approximately one half-life of the slGFP in DMSO treated cells) 
(Figure 5H). As a result, interfering with the microtubule cytoskeleton does not impact all misfolded 
proteins the same way. Misfolded proteins are partitioned through distinct degradation pathways and 
reach divergent intermediate states that are differentially susceptible to perturbations of the 
microtubule cytoskeleton. 
The short-lived proteins examined thus far are misfolded and targeted for degradation by 
chaperone-dependent PQC pathways (35,55). However, many short-lived proteins are degraded in 
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conjunction with regulated cell signaling pathways and not as a consequence of misfolding. Will 
disrupting the microtubule cytoskeleton affect solubility and degradation of a regulated, short-lived 
protein?  The transcription factor Cup9 is degraded in response to dipeptide levels in the cell by the 
N-end rule E3 ubiquitin ligase Ubr1 (57), thus representing a short-lived protein that is not misfolded 
but degraded in a regulated manner. To examine how benomyl affects the turnover and localization of 
Cup9, we used a yeast strain in which a GFP moiety was integrated into the CUP9 locus and 
expressed as a C-terminal tag (58). Benomyl treatment had no effect on the turnover of Cup9-GFP 
and did not alter the predominantly nuclear localization of Cup9-GFP (Figure 5.10A & B). Thus, the 
microtubule cytoskeleton does not influence solubility or degradation of all unstable proteins yet 
seems to impact quality control of select misfolded proteins.  
Microtubule dysfunction impairs slGFP recogtion by the ubiquitin receptors Rad23 and Rpn10  
As described above, the fate of slGFP is exquisitely sensitive to perturbations in various PQC 
stages. Disrupting the microtubule cytoskeleton drove slGFP to form insoluble aggregates however it 
is unclear at what stage in the life cycle of slGFP this defect is occurring. Polyubiquitination is a 
central step in targeting a misfolded protein to the proteasome for degradation (6). To determine if 
disrupting the microtubule cytoskeleton impairs slGFP polyubiquitination, cells expressing slGFP 
were treated with benomyl for 30 minutes and slGFP was immunoprecipiated from cell lysates. 
Ubiquitinated slGFP levels were increased after microtubule depolymerization (Figure 5.11A) 
suggesting that slGFP is still recognized by PQC machinery responsible for polyubiquitination 
however a downstream step in slGFP degradation is impaired.  
Several E3 ubiquitin ligases including Ubr1 and San1 bind non-native polypeptides (23,59) 
and function in PQC triage decisions (60). To determine if microtubule dysfunction disrupted 
interaction between Ubr1 and slGFP, Flag-Ubr1 was co-expressed with slGFP in yeast cells that were 
treated with DMSO or benomyl for 30 minutes. Flag-Ubr1 was isolated from yeast cell extracts via 
FLAG affinity resin and eluted with FLAG peptide. As shown in Figure 5.11B, slGFP is isolated  
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Figure 5.10. Degradation and localization of CupGFP is unaffected by benomyl. A) Turnover 
Cup9GFP expressed from endogenous CUP9 locus pretreated with DMSO or 40μM benomyl for 10 
minutes. Quantitation of three independent experiments is shown below where error bars represent 1 
SEM. B) Localization of Cup9GFP in wildtype and ∆ubr1 treated with DMSO or 40μM benomyl for 
30 minutes. 
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from cell extracts specifically when co-expressed with Flag-Ubr1 (lane 4) Under conditions of 
microtubule depolymerization we observe a slight decrease in the level of slGFP that is isolated with 
Flag-Ubr1 (lane 8).  However we consistently observe a slight decrease in the total level of slGFP in 
benomyl-treated samples that express Flag-Ubr1 and lysed under non-denaturing conditions (lane 8-
whole cell lysate). The ratio between slGFP in DMSO or benomyl treated samples is the same in the 
pull-down and whole cell lysate samples. This decrease might represent a pool of slGFP that is 
forming insoluble aggregates that are lost during extraction or reduced expression of slGFP in cells 
co-expressing FLAG-Ubr1. Interestingly, we consistently observed that Sis1, a Type II Hsp40 in 
yeast reproducibly eluted with Flag-Ubr1 while we could not detect Ydj1. This interaction was 
independent of the slGFP reporter (lanes 3 and 4) and was unaffected by benomyl (lanes 3 and 7). 
Thus, Ubr1 forms a complex with slGFP that is independent of the microtubule cytoskeleton. We 
were unable to detect an interaction between the slGFP reporter and tagged versions of San1. San1 
has polypeptide binding activity yet is also intrinsically disordered making this interaction 
particularly difficult to test (59). Regardless, polyubiquitinated forms of slGFP accumulate when the 
microtubule cytoskeleton is disrupted.  
Degradation of slGFP is hindered when this misfolded protein is partitioned into an insoluble 
state. Thus, even though slGFP is polyubiquitinated, slGFP aggregates might not be delivered to the 
proteasome. We investigated this hypothesis by identifying the ubiquitin receptors that participate in 
slGFP degradation. SlGFP was strongly stabilized a ∆rpn10 strain and partially stabilized in a ∆rad23 
strain background (Figure 5.11C). No effect was observed in ∆ddi1 and ∆dsk2 strains, two other 
ubiquitin receptors implicated in protein turnover (data not shown). Does deletion of RPN10 or 
RAD23 affect solubility of the slGFP reporter? SlGFP was predominantly triton-soluble in ∆rpn10 
and ∆rad23 strains (Figure 5.11D). Furthermore, slGFP was diffuse in ∆rpn10 and ∆rad23 strains 
under fluorescence microscopy (Figure 5.11E). Thus perturbing these post-ubiquitin steps in slGFP 
degradation does not drive this misfolded protein into an insoluble state.  
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Figure 5.11 Benomyl disrupts interaction between slGFP and the ubiquitin receptors Rad23 
and Rpn10. A) Ubiquitination of slGFP in cells treated with DMSO or benomyl. SlGFP was 
immunoprecipitated from cell lysates with anti-YFP antisera. Immunoprecipitated material was 
assessed by western blotting for ubiquitin and GFP. Input levels are shown on the left from whole cell 
lysates. Quantification of three independent experiments is shown on the right as a ratio of ubiquitin 
signal to level of immunoprecipitated GFP and normalized to WT. Error bars represent ±1SEM 
(*p<0.05). B) Interaction between slGFP reporter and Flag-Ubr1 in cells treated with DMSO or 
benomyl. Cell lysates were incubated with Flag resin and bound proteins were eluted with Flag 
peptide and analyzed by western immunbloting to for the indicated proteins. Input protein levels are 
shown on the right. C) Turnover of slGFP was analyzed in WT, ∆rad23 or ∆rpn10 strains by 
cycloheximide chase analysis. Quantification of three independent experiments is shown on the right.  
116  
 
 
Rpn10 and Rad23 display both overlapping as well as specific roles in protein degradation 
(61,62). Rpn10 resides predominantly as a subunit in the regulatory particle of the proteasome (63) 
while Rad23 association with the proteasome occurs through its ubiquitin-like domain (64). We were 
interested if benomyl treatment abrogated interaction between slGFP and either Rpn10 or Rad23. 
TAP-tagged versions of Rpn10 and Rad23 were expressed from their endogenous promoters to 
facilitate isolation of a complex with slGFP. SlGFP was isolated with both Rad23-TAP and Rpn10-
TAP. Importantly, depolymerizing microtubules resulted in a large decrease in the quantity of slGFP 
in complex with either Rad23-TAP or Rpn10-TAP (Figure 5.11F). We were unable to perform the 
reciprocal pulldown through the slGFP due to background binding between the TAP tag and antisera 
employed to immunoprecipitate slGFP. These data suggest that depolymerization of microtubules 
prevents the slGFP from being recognized by ubiquitin receptors responsible for its degradation. 
Microtubule depolymerization interferes with chaperone binding to slGFP 
Disrupting microtubule dynamics drives slGFP off-course from its pathway to the proteasome 
and results in the formation of insoluble aggregates. Molecular chaperones normally prevent non-
native polypeptides from self-associating into insoluble aggregates. As a result, we were curious how 
diverting slGFP into this insoluble state influence interaction with molecular chaperones. We 
observed that the Type I Hsp40 Ydj1 is required to hold slGFP after polyubiquitination. SlGFP co-
immunoprecipitated with Ydj1 from yeast cell extracts (Figure 8A lane 3). However there was a 
substantial decrease in the level of slGFP that co-immunoprecpitated with Ydj1 in samples treated 
with benomyl as early as 15 minutes (Figure 5.12A lane 4 and Figure 5.13A). The Ydj1:slGFP 
complex was independent of Hsp70 because slGFP co-immunoprecipitated with a mutant form of 
Ydj1 that is unable to interact with Hsp70 suggesting this interaction is specific (Figure 5.13B) 
 
Figure 5.11  . . . cont. D) Triton-solubility of the slGFP reporter after high-speed centrifugation in the 
indicated strain background (T-total, S-supernatant, P-pellet). E)  Fluorescence microscopy of slGFP 
in the indicated strain background. F) TAP-pulldown of slGFP in yeast strain expressing Rpn10-TAP 
or Rad23-TAP treated with DMSO or benomyl. 
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Figure 5.12 Benomyl treatment selectively disrupts chaperone interactions with slGFP. A) Ydj1 
and Sis1 were co-immunoprecipitated from cells treated with DMSO or benomyl. Whole cell lysates 
are shown on the right. B) Co-immunoprecipitation of Ssa1 from cells treated with DMSO or 
benomyl. Lysates were divided in half and one set treated with Apyrase (lower panel). Then lysates 
were incubated with anti-Ssa1 antisera or no antibody (-ab). Whole cell lysates are shown on the 
right. C) Cells transformed with an empty vector or GFP-Tub1 and treated with DMSO or benomyl. 
Cell lysates were incubated with anti-YFP antisera and assessed for chaperone levels. D) Cells 
expressing GFP-Tub1 were treated with DMSO and benomyl and Ydj1 co-immunoprecipitated with 
anti-Ydj1 antisera.  
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(65). SlGFP also co-immunoprecpitated with Sis1 however this interaction was unaffected by 
microtubule depolymerization. Interaction between Sis1 and slGFP was independent of either Ubr1 or 
San1 demonstrating that this complex was not indirectly occurring through the E3 ligase (Figure 
5.13C). Of note, we observed a small amount of Ydj1 that co-immunoprecipitated with the Sis1 anti-
sera. This might be due to cross-reactivity with the conserved Ydj1 J-domain or a consequence of 
shared binding partners such as Ssa1. Regardless, this does not appear to influence the level of slGFP 
reporter that co-immunoprecipitated with Sis1 because this interaction was consistently insensitive to 
benomyl treatment. Furthermore, benomyl treatment did not affect the solubility of these chaperones 
indicating that reduced binding was not a consequence of Ydj1 or Ssa1 forming triton-insoluble 
aggregates (Figure 5.13D). If binding between slGFP and an Hsp40 is reduced upon microtubule 
depolymerization, we expected that interaction between slGFP and an Hsp70 would also be 
decreased. SlGFP co-immunoprecipitated with Ssa1 (Figure 5.12), an Hsp70 isoform that is 
associated with degradation of several misfolded proteins (34,37,66,67). This interaction was 
enhanced when cell lysates were treated with Apyrase to deplete ATP, consistent with the ATP-bound 
form of Hsp70 having lower substrate affinity (Figure 5.12). Benomyl treatment reduced the level of 
slGFP that co-immunoprecipitated with Ssa1 in the presence or absence of Apyrase (Figure 5.12 
lower panel). Therefore, slGFP is a poor substrate for Ydj1and Ssa1when microtubule dynamics are 
disrupted.   
Both Ydj1 and Ssa1 are previously implicated in the recovery of the microtubule cytoskeleton 
after depolymerization with benomyl (68). Benomyl treatment might release free tubulin monomers 
that bind Ydj1 or Ssa1 and titrate these molecular chaperones from other cellular substrates including 
slGFP. To test this hypothesis, we examined how benomyl affected interaction between Ydj1, Ssa1 
and tubulin. We were unable to detect an interaction between Ydj1 or Ssa1 with endogenous tubulin 
which migrated at the same molecular weight as the IgG heavy chain. To overcome this obstacle, we 
expressed GFP-Tub1 in yeast cells. This GFP-fusion protein was expressed to approximately 3-fold  
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Figure 5.13. Chaperone interaction with slGFP after benomyl treatment.  A) Levels of slGFP 
reporter that co-immunoprecipitated with Ydj1 and Sis1during benomyl timecourse (left panel). Total 
protein levels from whole cell lysates are shown on the right. B) Levels of slGFP that co-
immunoprecipitated with wildtype Ydj1 or ydj1(H34Q) (left panel). In this experiment, rabbit 
preimmune antisera shows background levels of slGFP in the co-IP.  Total levels from whole cell 
lysates are shown on the right. C) Levels of slGFP that co-immunoprecipitated with Ydj1 or Sis1 
antisera in WT, ∆ubr1, or ∆san1 strain background. D) Solubility of tubulin, Pgk1, Ssa1, Ydj1, and 
Sis1 after treatment with DMSO or 40μM benomyl for 30 minutes (T-total, S-supernatant, P-pellet).. 
E) Turnover of slGFP reporter in cells expressing GFP-Tub1 for 2 hours. SlGFP reporter was 
detected using an HA epitope in N-terminus.  
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above enodogenous tubulin yet still incorporates into endogenous microtubules (51) and did not affect 
turnover of the slGFP reporter (Figure 5.13E). Both Ydj1 and Ssa1 co-immunoprecipitated with GFP-
Tub1 however benomyl had no effect on this interaction (5.12C). Furthermore, benomyl had no effect 
on the level of GFP-Tub1 that co-immunoprecpitated with Ydj1 (Figure 5.12D) suggesting that 
benomyl treatment was not altering the interaction between Ydj1 and tubulin.  
Elevating Sis1 levels rescues slGFP degradation in the absence of a functional cytoskeleton 
 If perturbing the microtubule cytoskeleton interferes with chaperone recognition, we were 
curious if elevating levels of Ydj1 or Sis1 could partition slGFP back into a soluble state competent 
for degradation. Overexpressing Ydj1 from a strong, constitutive promoter had no effect on the 
degradation of slGFP. However, elevating Sis1 levels accelerated slGFP turnover (Figure 5.14A). 
Both Ydj1 and Sis1 could be expressed approximately 5-fold over endogenous levels (Figure 5.14B). 
Thus, these two Hsp40 co-chaperones exert distinct functions on the same misfolded protein.  
 If increasing Sis1 levels accelerates slGFP degradation, we were interested if Sis1 
overexpession could rescue slGFP degradation after microtubule depolymerization. Indeed, while 
benomyl treatment delays slGFP turnover, overexpression of Sis1 still accelerated slGFP degradation 
to about the same kinetics as in the absence of benomyl (Figure 5.14C). Notably, Sis1 overexpression 
did not impact slGFP solubility (Figure 5.14D) or the presence of slGFP aggregates (Figure 5.14E). 
As a result, Sis1 was likely not acting as a holdase to maintain slGFP in a soluble state. Instead, Sis1 
might function directly on slGFP aggregates to promote degradation. To test this hypothesis, we 
examined the fate of benomyl-induced slGFP aggregates in the presence of excess Sis1. Cells were 
treated with benomyl for 30min then protein synthesis inhibited with cycloheximide. Large, slGFP 
aggregates were typically stable over a 20min period however we observed a reduction in the number 
of cells with large, single aggregates at 20min when Sis1 levels were elevated (Figure 5.14F). 
Consequently, Sis1 appears to participate in the removal of slGFP aggregates after microtubule 
depolymerization thus acting as an auxiliary mechanism for the disposal of misfolded polypeptides 
that have assembled into aggregates.  
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Figure 5.14. Elevation of Sis1 levels accelerates slGFP turnover. A) Turnover of slGFP in cells 
transformed with an empty vector, a plasmid overexpressing Ydj1 (GPD-Ydj1) or Sis1 (GPD-Sis1). 
Quantification of three independent experiments examining turnover of slGFP with overexpressed 
Sis1. B) Whole cell lysates from cells overexpressing Ydj1 or Sis1. C) Turnover of slGFP in cells 
pretreated with benomyl transformed with an empty vector or a plasmid overexpressing Sis1. 
Quantification of three independent experiments is shown on the right. D) Solubility of slGFP in cells 
pretreated benomyl with overexpressed Sis1 (T-total, S-supernatant, P-pellet). E) Localization of 
slGFP in cells pretreated with benomyl and overexpressed Sis1 (a longer exposure normalized to the 
intensity in an empty vector sample is shown on the right). F) Localization of slGFP in cells 
pretreated with benomyl then treated with cycloheximide after the indicated time.  
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5.4 Discussion  
Misfolded proteins are strongly predisposed to spontaneous self-assembly into  protein 
aggregates that threaten cellular homeostasis (1). While PQC pathways exert enormous resources to 
prevent protein aggregation, we find that interfering with specific stages in the degradation of a 
misfolded protein drives this protein to aggregate in the cytosol (Figure 5.15). Disrupting PQC stages 
that function after polyubiquitination appear to predispose this misfolded protein to form insoluble 
aggregates that are poorly recognized by ubiquitin receptors and molecular chaperones. Polyubiquitin 
chains might inherently drive protein aggregation and thus abundant molecular chaperone such as 
Ydj1 are required to maintain polyubiquitinated proteins in a soluble state. Interestingly, elevating 
Sis1 levels restores degradation demonstrating that multiple chaperone pathways exist in the cell to 
remove non-native polypeptides in monomeric as well as assembled states.  
The cell likely favors holding misfolded proteins in a soluble state. Indeed, PQC networks are 
robust enough to tolerate the accumulation of misfolded proteins as we observed when either Ubr1 or 
San1 were absent. Under these conditions, pools of slGFP were sequestered in a single, juxtanuclear 
aggregate yet maintained in a soluble state. This aggregate resembles the JUNQ compartment 
however Kaganovich et al demonstrated that recruitment to this location required ubiquitination. 
Redundant E3 pathways might be sufficient to ubiquitinate low levels of the slGFP reporter that self-
assemble with un-ubiquinated pools and recruit this complex to the JUNQ compartment. 
Alternatively, these aggregates may represent a distinct subcellular compartment. Regardless, 
sequestration of misfolded proteins  via the microtubule cytoskeleton into subcellular inclusions 
appears to be a widely employed mechanism to protect cells from protein misfolding  and aberrant 
aggregation (44). 
Surprisingly, there is a basal requirement for an intact microtubule cytoskeleton to prevent 
misfolded proteins from self-assembling into aggregates. The precise role of the microtubule 
cytoskeleton in PQC is unclear. Microtubules might facilitate trafficking of polyubiquitinated protein 
species to the proteasome. In this model, microtubule motors would be predicted to connect  
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Figure 5.15 Model for PQC pathways that participate in degradation of misfolded cytosolic 
proteins and consequence of interference with specific components.   
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polyubiquitinated proteins to the microtubule cytoskeleton and ferry these proteins selectively to the 
proteasome which is predominantly located at the ER membrane and nucleus (42,69). We did not 
observe a requirement for the minus-end motors Dyn1 or Kar3 in degradation of slGFP (data not 
shown). However there are numerous other microtubule binding proteins that could act as conduits 
between the microtubule cytoskeleton and PQC machinery. Disruption of this pathway would cause 
polyubiquitinated proteins to accumulate in the cytosol. Polyubiquitinated proteins are normally 
shuttled to the JUNQ however this pathway likewise requires the microtubule cytoskeleton (42). As a 
result, misfolded proteins such as slGFP are caught in an intermediate state and accumulate in 
aggregates that are poorly recognized by ubiquitin receptors and not delivered to the proteasome. 
Disrupting the microtubule cytoskeleton reduced binding between slGFP and the molecular 
chaperones Ydj1 and Ssa1. While reduced binding might reflect slGFP aggregating and burying 
polypeptide binding sites, the microtubule cytoskeleton might act as a scaffold for interactions 
between molecular chaperones and misfolded proteins. Scaffolding of PQC components might favor a 
stable complex that holds a misfolded protein in a soluble state long enough for recognition by 
ubiquitin receptors and delivery to the proteasome.  
The results described herein further demonstrate that aggregation per se does not render a 
misfolded protein insensitive to proteasomal degradation. For example, VHL forms aggregates upon 
microtubule dysfunction yet degradation is accelerated. Presumably there are back-up pathways that 
facilitate solubilization of aggregated proteins (ex. Hsp104) (70). Why are VHL aggregates detergent-
soluble when slGFP aggregates are detergent-insoluble? Intrinsic properties within these two 
misfolded proteins might predispose one or the other to assemble into distinct aggregates. 
Alternatively, unique binding partners might hold VHL in a soluble state. Still, why is VHL 
degradation accelerated after benomyl treatment? Folding of VHL requires the TriC chaperonin 
complex (53). TriC also participates in folding of tubulin (71,72). Accordingly, microtubule 
depolymerization might disrupt TriC activity generating larger pools of unfolded VHL in the cell. 
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TriC is not required for VHL degradation (55) so pathways that target unfolded VHL for degradation 
are still intact to degrade this excess pool.  
Misfolded proteins are funneled through distinct PQC complexes that alter the fate of that 
protein and the predisposition to form insoluble aggregates. For example, slGFP degradation requires 
Ydj1, a co-chaperone that is dispensable for VHL degradation (55). Similar to benomyl treatment, 
deletion of YDJ1 did not inhibit slGFP ubiquitination however this misfolded protein was partitioned 
into an insoluble state suggesting both Ydj1 and the microtubule cytoskeleton are required to hold 
polyubiquitinated forms of slGFP in a soluble state. While Ydj1 has been previously linked to 
ubiquitination of several unstable proteins (22,35,48) Ydj1 also acts with Ssa1 downstream of 
ubiquitination to hold another cytosolic, misfolded protein in a soluble state (67). Thus, Ydj1’s 
function in protein degradation is substrate-specific. Sis1 contributes a distinct role to PQC. Elevating 
Sis1 levels might partition slGFP into an alternative degradation pathway that is independent of the 
microtubule cytoskeleton. Sis1 has also been implicated with Hsp104 in the shearing of prion fibrils 
(73,74). Accordingly, Sis1 might recruit Hsp104 to slGFP aggregates and promote unfolding of 
assembled domains to enhance degradation efficiency.  Importantly, overlapping PQC networks 
maintain protein homeostasis by diverting misfolded proteins through various intracellular pathways 
that ultimately remove aberrant protein species from the cytosol.  
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5.5 Materials and Methods 
Yeast strains, growth conditions, and reagents 
Strains were generated using the lithium acetate transformation method. Freshly transformed colonies 
were used to inoculate synthetic drop-out media lacking specific amino acids to maintain cultures 
under selection and incubated at 30°C throughout the experiment unless otherwise noted. Cells 
transformed with pESC-GFP-VHL were grown overnight prior to the experiment in 2% galactose as 
previously described (55). Cells transformed with pGAL-GFP-Tub or pGAL-tub1(E255A) were 
grown overnight under selection in 2% raffinose prior to the addition of galactose. Benomyl (Sigma) 
was dissolved in DMSO as a 40mM stock immediately prior to experiment. Cells were treated at a 
final concentration of 40μM in all experiments for the indicated times. Guanidine hydrochloride 
(Fisher) was dissolved in sterile H2O at stock concentration of 6M.  
Cycloheximide-chase analysis  
Yeast cultures expressing the indicated proteins were induced or treated with chemicals as described 
in the text. To inhibit protein translation, cultures were treated with 200μg/mL cycloheximide 
(SIGMA) and aliquots removed at indicated time points. Cells were lysed by alkaline pretreatment 
(75). Briefly, cells were resuspended jn 0.1M NaOH and incubated for 5min at room temperature, 
washed in sterile, H2O, and boiled for 15min in denaturing lysis buffer (60mM Tris-HCl pH6.8, 
2%SDS, 2mM DTT). Cell lysates were precleared at 3,000rpm for 3min and the supernatant 
normalized using BioRad protein determination. Normalized lysates in sample buffer (60mM Tris-
HCl pH 6.8, 2% SDS, 10% glycerol, 2mM EDTA, 5% β-mercaptoethanol, 1mg/mL bromophenol 
blue) were analyzed by SDS-PAGE and western immunoblotting for the indicated proteins. 
Co-immunoprecipitation analysis of protein complexes 
Yeast strains expressing the indicated proteins were lysed by glass bead disruption in  Buffer A 
(150mM NaCl, 50mM Hepes pH7.4, 1mM EDTA, 0.1% Triton X, 1mM PMSF, and 1x yeast 
protease inhibitor cocktail [Roche]). Cell extracts were precleared at 3,000xg for 3min at 4°C. The 
supernatant was saved and protein concentrations assessed with a BioRad protein determination kit. 
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Protein concentrations were normalized between samples to approximately 3 mg/mL and 300μg of 
protein incubated with the indicated antisera for 1 hour at 4°C then incubated with Protein G beads 
(50% slurry preblocked with BSA from Roche) for 30min at 4°C. Beads were washed 2-3 times with 
Buffer A then resuspended in sample buffer and analyzed by SDS-PAGE and western 
immunoblotting.  
Detection of ubiquitinated forms of slGFP reporter  
Yeast strains expressing the slGFP report were grown under selection in mid-log phase. Cells were 
washed with cold H2O (+1mM NaN3 and 20mM NEM) and lysed by glass bead disruption in Buffer 
A (+1mM NEM). Cell extracts were precleared at 3,000 rpm for 3min at 4°C, protein concentrations 
normalized, and GFP immunoprecipitated with anti-YFP antisera and protein G resin (Roche) using 
standard methods. Protein G resin was washed three times in Buffer A supplemented with 0.1% SDS. 
Ubiquitinated forms of slGFP were detected after SDS-PAGE and western immunoblotting for 
ubiquitin (Covance). Ubiquitinated slGFP reporter levels were quantified using ImageJ software 
(NIH) and normalized as a ratio to the level of slGFP that was immunoprecipitated from the lysate 
(detected using anti-GFP [Roche]).  
Fluorescence microscopy 
Yeast strains expressing the indicated proteins and treated as described in the text were fixed in 3.7% 
formaldehyde and stored in phosphate buffered saline (pH 7.5) supplemented with 1.2M sorbitol. 
Fixed cells were permeabilized and DNA visualized with DAPI as described in (76). Rnq1-mRFP 
was expressed from the GAL1 promoter for 4 hours before cells were processed as described. Cells 
were visualized with an Olympus IX81 Fluorescence microscope and images processed with 
Metamorph software.  Exposure times and all other settings were standardized across individual 
experiments unless otherwise noted.  
TAP pulldown for slGFP reporter  
Yeast strains expressing Rad23-TAP or Rpn10-TAP were transformed with pCUP-slGFP reporter 
were induced with 100μM CuSO4 for 1 hour and treated with DMSO or 40μM benomyl for 30 
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minutes. Cells were collected by centrifugation and washed in cold H2O (+ 1mM NaN3 and 20mM 
NEM). Cells were lysed by glass bead disruption in Buffer A(+NEM) and lysates pre-cleared at 
3,000rpm for 3min at 4°C. The supernatant was normalized and aliquots were incubated with Rabbit 
IgG resin (Sigma) for 1 hour at 4°C and washed 2 times with buffer A. The resin was resuspended in 
sample buffer and analyzed by SDS-PAGE and western immunoblotting for GFP (Roche) and TAP 
(Genscript).  
Differential high speed centrifugation 
Yeast strains expressing slGFP were treated with DMSO or 40μM benomyl for 30min. Cells were 
lysed by glass bead disruption in Buffer A (+1mM DTT) and lysates pre-cleared at 3,000 rpm for 
3min at 4°C. The supernatant was saved and 200μg protein spun at 100,000xg for 30min at 4°C. An 
aliquot was saved prior to the spin to represent the total input. Equivalent volumes from total, 
supernatant, and pellet fractions were added to 2x sample buffer and analyzed by SDS-PAGE and 
western immunoblotting for the indicated proteins.  
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Chapter Six 
Final Conclusions and Future Directions 
 
136 
 
6.1. Introduction 
 Protein misfolding is the underlying cause of an extensive group of human diseases known 
collectively as “conformational disorders” (1). Complex protein quality control networks target non-
native polypeptides for refolding, degradation, or in some cases, protective aggregation (2-4). 
Molecular chaperones encounter enormous diversity in non-native protein conformers. These might 
include polypeptides enriched in hydrophobic residues as well as beta-rich, amyloid-like fibrils that 
accumulate in diseases such as Alzheimer’s disease and Huntington’s disease (5). How protein 
quality control components such as molecular chaperones discriminate between these various protein 
conformers and efficiently triage non-native proteins between refolding, degradation, or protective 
aggregation is a major unanswered question in the field.  
 The studies described herein contribute two significant points to this question. First, the Type 
I Hsp40 Ydj1 recognizes diverse non-native polypeptides including amyloid-like conformers by 
utilizing various combinations of unique chaperone modules. Thus, Ydj1 is an adaptable molecular 
chaperone that can tether Hsp70 function to a wide variety of non-native polypeptides to suppress 
protein aggregation or influence triage decisions. Second, the microtubule cytoskeleton is required for 
maintaining some misfolded proteins in a soluble state competent for degradation. Interfering with the 
microtubule cytoskeleton not only impairs degradation of specific misfolded proteins but also disrupts 
trafficking of misfolded proteins to quality control compartments, illustrating a novel and extensive 
role for the microtubule cytoskeleton in protein quality control. How molecular chaperones and the 
microtubule cytoskeleton cooperate to suppress aggregation and promote degradation of misfolded 
proteins is a future area of study.  
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 6.2 The Hsp40 co-chaperone Ydj1 utilizes multiple polypeptide binding sites to regulate protein 
folding and suppress aggregation.  
The Hsp70/Hsp40 molecular chaperone system is an ancient quality control pathway that 
protects cells from misfolded protein conformers (6). Hsp70s are abundant cellular proteins, yet very 
limited in diversity and exhibit broad substrate selectivity (7,8). As a result, specification of Hsp70 
activity is conferred by the more expanded Hsp40 family that stimulates Hsp70 ATP hydrolysis via 
action of a conserved J-domain (9,10). Importantly, these J-domain containing proteins have evolved 
diverse protein:protein interaction domains that couple Hsp70 polypeptide binding to numerous 
cellular activities including protein refolding and degradation (11).  
The yeast Type I Hsp40 Ydj1 is one of the more well-characterized members of the Hsp40 
co-chaperone family. Ydj1 is implicated in a plethora of cellular activities including protein 
translocation across membranes, cell cycle, protein folding, protein degradation, prion propagation 
and many other functions (12-17). Ydj1 is the most abundant Hsp40 in budding yeast (119,000 
mol/cell)(18) however high concentration does not account for such broad influence. Ydj1 interacts 
with highly disparate non-native clients including polypeptides enriched in hydrophobic residues (19) 
as well as beta-sheet rich, amyloid-like substrates (20-22). A perplexing question is how might a 
single molecular chaperone recognize such diverse non-native conformations? 
Ydj1 utilizes at least three independent domains to interact with non-native polypeptides. For 
example, a hydrophobic pocket in the C-terminal domain of Ydj1 binds short, hydrophobic 
polypeptides (23). Computational analysis of Ydj1-bound peptides from multiple studies identified a 
consensus binding sequence that is found a wide variety of yeast proteins (24). Thus, Ydj1 scans the 
cellular environment for exposed hydrophobic sequences that are prevalent in unfolded polypeptides 
and prevents these proteins from self-associating into aggregates (16,25).  
 In addition, the zinc finger-like region (ZFLR) of Ydj1 contributes to interaction with a 
subset of Ydj1 clients including glutamine-enriched prions such as the yeast prion protein Rnq1 (21). 
Ydj1 actually prefers to bind Rnq1 in its beta-sheet rich, amyloid-like [RNQ
+
] prion conformation. 
138 
 
The Ydj1 ZFLR is composed of two beta-strands that extend from the Ydj1 C-terminal domain (26) 
and might interact with a beta-enriched substrate via a donor strand exchange mechanism previously 
described for bacterial chaperones (27,28). Site-directed mutagenesis of solvent-exposed, hydrophilic 
residues in these beta-strands is one way to test this hypothesis. Consequently, the Ydj1 ZFLR 
supplies an additional protein interaction surface to selectively bind non-native proteins enriched in 
beta-structure.  
Ydj1 employs at least one additional feature to bind non-native proteins. Ydj1 is farnesylated 
at a C-terminal CaaX motif (29) and this lipid modification is required for interaction with the 
glutamine/asparagine-rich prion domain from Rnq1 (21) as well as the Hsp90 client Ste11 (30). 
Whether the Ydj1 farnesyl moiety directly binds non-native proteins or contributes indirectly via 
interaction with a membrane bilayer is an open question. Both scenarios are feasible because the 
farnesyl moiety could interact with hydrophobic residues in an unfolded polypeptide and stabilize a 
Ydj1:substrate interaction long enough for efficient transfer to Hsp70. Farnesylation of Ydj1 is 
required for localizing a small pool of this chaperone to the ER membrane (29). How membrane 
localization impacts chaperone activity is a relatively unexplored question though some misfolded, 
cytosolic proteins need to be recruited to the ER membrane for efficient degradation (31). 
Importantly, farnesylation is required for only a subset of Ydj1:substrate interactions (21) so more 
information is required on how lipid modification of a molecular chaperone confers specificity in 
substrate interaction. All studies analyzing Ydj1 activity in vitro purified Ydj1 from bacteria and thus 
utilized a form that is not farnesylated. Ydj1 should be purified from yeast cell extracts and used in 
future studies to explore how farnesylation impacts direct binding between Ydj1 and non-native 
substrates. In addition, more rigorous analysis is required to determine how ER-localization 
contributes to Ydj1 function. For example, how Ydj1 is targeted specifically to the ER membrane is 
unknown and what additional protein quality control components function with Ydj1 at this surface is 
also an ongoing question. To address this issue, Ydj1 can be targeted to other subcellular 
compartments by the addition of various localization signals (ex. nuclear localization signal). 
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Alternatively Ydj1 can be constitutively tethered to the ER membrane via the addition of C-terminal 
tail anchored domains that are post-translationally inserted into the ER membrane (32).  
Altogether, a model emerges in which Ydj1 scans the yeast cytosol for non-native protein 
conformers utilizing at least three distinct chaperone modules that cooperatively select a diverse array 
of non-native polypeptides for interaction. Loss of an individual binding module selectively interferes 
with a subset of Ydj1:client interactions with varying effects on cell physiology. For example, loss of 
the ZFLR or farnesyl moiety confers sensitivity to heat stress (29,33) as well as aggregation of 
amyloid-like proteins (21). Multiple chaperone binding sites not only expands the repertoire of 
potential clients, specific Ydj1:substrate contacts could orient a Ydj1 client in a distinct conformation 
in relation to the J-domain influencing interaction with downstream chaperones including Hsp70, 
Hsp90, E3 ubiquitin ligases, etc and thus facilitate triage between refolding or degradation. We still 
lack a structural understanding of this process and solving X-ray crystal structures of diverse 
Ydj1:client complexes will be of significant value in the future.  
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6.3 The cooperative action of molecular chaperones and the microtubule cytoskeleton protect 
cells from aggregation of misfolded proteins   
 The cell devotes enormous resources to the selective recognition of non-native protein 
conformers and triage of these polypeptides between repair or degradation pathways. This “decision” 
is not to be taken lightly as the cell needs to prevent aberrant protein aggregation while maintaining a 
pool of functional proteins to carry out essential cellular processes (34). Protein aggregates are 
conventionally poor substrates for the proteasome (35) and could interfere with cellular folding 
equilibrium by titrating chaperones away from essential tasks or directly inducing the misfolding of 
native proteins (36-38). However, protein aggregation in the form of facilitated compartmentalization 
is a mechanism by which cells actively sequester non-native polypeptides under conditions of stress 
(3,39). Furthermore, facilitated assembly of amyloid-like aggregates is protective in some models for 
neurodegeneration (40-42). Consequently, diverse misfolded proteins are processed by sophisticated 
protein quality control networks that shuttle these polypeptides between distinct outcomes.  
To shed light on this process, I characterized a cytosolic reporter protein that is misfolded and 
degraded by the ubiquitin proteasome system. When proteasome activity is inhibited, this misfolded 
protein traffics through two recently described quality control compartments; a juxtanuclear 
compartment that houses soluble, polyubiquitinated proteins called the JUNQ and a perivacuolar 
compartment called the IPOD that stores insoluble, amyloidogenic proteins (43). Efficient 
degradation of this misfolded reporter was dependent upon the Hsp40 co-chaperone Ydj1, the E3 
ubiquitin ligases Ubr1 and San1, and surprisingly the microtubule cytoskeleton.  
The Hsp40/Hsp70 system functions at the front lines of protein quality control through 
binding non-native polypeptides. This chaperone machine is a potent suppressor of protein 
aggregation (20-22,25). While Ydj1 has been previously linked to stimulating polyubiquitination in 
conjunction with E3 ubiquitin ligases (13,21,44,45), Ydj1 is also required to hold misfolded proteins 
in a soluble state independent of ubiquitination. Surprisingly, interfering with microtubule dynamics 
disrupts interaction between Ydj1 and misfolded proteins. This observation reveals a surprising, novel 
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link between chaperone-dependent suppression of protein aggregation and the microtubule 
cytoskeleton.   
How does the microtubule cytoskeleton contribute to protein quality control?  Microtubule 
dysfunction did not impair ubiquitination of the misfolded proteins examined thus far suggesting 
microtubules are required for holding polyubiquitinated proteins a soluble state. In a crowded cellular 
environment, microtubules might stabilize chaperone:substrate complexes long enough for refolding 
or degradation pathways to process a non-native polypeptide for polyubiquitination and delivery to 
the proteasome. Alternatively, polyubiquitinated proteins might be trafficked to the proteasome by 
action of microtubule motors. Disrupting this step would likewise result in the accumulation of 
polyubiquitinated proteins that would have a high propensity to aggregate and might be poor 
substrates for molecular chaperones such as Ydj1. Identifying the molecular conduits between the 
microtubule cytoskeleton and misfolded proteins will greatly enhance our understanding of protein 
quality control pathways function in the crowded cytosol.  
Interestingly, microtubule dysfunction impacts aggregation and degradation of specific 
misfolded proteins. For example, depolymerization of the microtubule cytoskeleton induces 
aggregation of von Hippel Lindau (VHL) protein yet degradation of VHL is actually accelerated. 
VHL misfolded conformers are either less predisposed to assemble as insoluble aggregates or VHL is 
recognized by specialized chaperone complexes that hold this protein in a soluble state. 
Consequently, conformational subtleties in misfolded proteins can influence selective recognition by 
unique chaperone complexes as well as propensity to assemble into degradation-incompetent 
aggregates.  
Finally, protein aggregation is a fundamental threat to cellular homeostasis. However protein 
quality control pathways are exquisitely adapted to suppress aberrant protein aggregation as well as 
facilitate specialized assembly of non-native polypeptides into protective, compartmentalized 
structures (Figure 6.1). The first line of defense appears to rely on preventing protein aggregation. 
Hence, Hsp70 molecular chaperones are abundant proteins with broad polypeptide preferences to 
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manage the large scale burden of protein misfolding in the cytoplasm (6,7). Some Hsp40 co-
chaperones such as Ydj1 are also very abundant yet possess more select binding specificities and 
unique protein interaction domains (46). These molecular chaperones are also stress-inducible such 
that the cell is able to compensate under  conditions when bulk protein misfolding (ex. heat stress) 
(47).  
However, a back-up system is also in place when this first protective layer becomes 
overwhelmed. Cellular pathways sequester misfolded proteins in specialized compartments including 
the JUNQ and IPOD (43). This form of protective aggregation serves distinct functions. First, quality 
control compartments such as the JUNQ store polyubiquitinated proteins when proteasome function 
is inhibited (39,43). As a result, misfolded proteins that pass through chaperone/E3 ligases 
checkpoints yet are unable to be degraded are maintained in a soluble state. The IPOD is an additional 
layer of support by acting as a deposition site for misfolded proteins that have adopted an amyloid-
like, or insoluble conformation. This compartment might be especially important under conditions of 
prolonged stress when misfolded proteins accumulate beyond the capacity of the Hsp70/Hsp40 
system. In yeast, the IPOD also might facilitate propagation of yeast prions (48) or help retain 
chronically misfolded proteins in the mother cell during cell division (49). While the JUNQ and 
IPOD are most prominent under conditions of stress these quality control compartments might 
contribute to basal protein quality control. Future studies should identify the receptors and motor 
molecules that selectively deliver misfolded proteins to these compartments. How are misfolded 
proteins selectively partitioned between these compartments by the cooperative action of molecular 
chaperones, E3 ligases, and the microtubule cytoskeleton? Answering these questions will elevate our 
understanding of the sophisticated protein quality control networks that protect the cellular 
environment.  
143 
 
 
Figure 6.1 Degradation pathway of a cytosolic, misfolded protein by chaperone action and 
subcellular compartmentalization. When a native protein misfolds in the cytosol, molecular 
chaperones including Hsp40/70 family members bind unfolded sequences in this protein. If this 
misfolded protein escapes this quality control step, then this non-native protein could assemble into 
insoluble aggregates. Alternatively, this protein could be trafficked to the IPOD with other insoluble 
proteins. If the misfolded protein is held in a soluble state, then additional degradation cofactors such 
as E3 ligases could be recruited to promote polyubiquitination. Some E3 ligases such as CHIP can act 
as chaperones to suppress protein aggregation and influence triage between refolding and 
degradation. If proteasome activity is jeopardized, polyubiquitinated proteins are stored in a soluble 
state at the JUNQ compartment and subsequently degraded if proteasome activity is restored. If the 
polyubiquitinated protein escapes from this chaperone complex or if the microtubule cytoskeleton is 
impaired, this protein might assemble into insoluble aggregates. However, auxiliary pathways that 
might include the Hsp40 Sis1 and/or the AAA Type ATPase Hsp104 appear to solubilize some 
aggregates in the cell.  
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